uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.958 | Q17 | What gene does the drug Rolapitant Hydrochloride target? | The drug Rolapitant Hydrochloride targets the gene TACR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rolapitant hydrochloride%" OR LOWER(tradeNames_string) LIKE "%rolapitant hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%rolapitant hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3346', 'drugName': 'Rolapitant Hydrochloride', 'tradeNames_string': 'Varubi', 'drugSynonyms_string': 'Rolapitant hcl h20, Rolapitant hydrochloride, Rolapitant hydrochloride monohydrate, SCH-619734, SCH619734', 'linkedDiseasesDrug_string': 'Sarcoma (EFO_0000691), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.929 | Q17 | What gene does the drug Mibefradil target? | The drug Mibefradil targets 3 genes: CACNA1G, CACNA1I and CACNA1H. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mibefradil%" OR LOWER(tradeNames_string) LIKE "%mibefradil%" OR LOWER(drugSynonyms_string) LIKE "%mibefradil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_835', 'drugName': 'Mibefradil', 'tradeNames_string': 'Posicor 100, Posicor 50', 'drugSynonyms_string': 'Mibefradil, Posicor', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Cardiovascular Disease (EFO_0000319), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA1G (ENSG00000006283), CACNA1I (ENSG00000100346)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_291', 'drugName': 'Mibefradil Dihydrochloride', 'tradeNames_string': 'Posicor', 'drugSynonyms_string': 'Mibefradil dihydrochloride, Mibefradil hydrochloride, RO 40-5967/001', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA1G (ENSG00000006283), CACNA1I (ENSG00000100346)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.112 | Q17 | What gene does the drug Inclisiran Sodium target? | The drug Inclisiran Sodium targets the gene PCSK9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inclisiran sodium%" OR LOWER(tradeNames_string) LIKE "%inclisiran sodium%" OR LOWER(drugSynonyms_string) LIKE "%inclisiran sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4738', 'drugName': 'Inclisiran Sodium', 'tradeNames_string': 'Leqvio', 'drugSynonyms_string': 'Inclisiran sodium, Leqvio sodium', 'linkedDiseasesDrug_string': 'Atherosclerosis (EFO_0003914), Familial Hypercholesterolemia (EFO_0004911)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PCSK9 (ENSG00000169174)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1240 | Q17 | What gene does the drug Goserelin Acetate target? | The drug Goserelin Acetate targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%goserelin acetate%" OR LOWER(tradeNames_string) LIKE "%goserelin acetate%" OR LOWER(drugSynonyms_string) LIKE "%goserelin acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_246', 'drugName': 'Goserelin Acetate', 'tradeNames_string': 'Novgos, Zoladex, Zoladex la', 'drugSynonyms_string': 'Fertilan, Goserelin Acetate, Goserelin acetate', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Fallopian Tube Cancer (MONDO_0002158), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Male Breast Carcinoma (EFO_0006861), Metabolic Syndrome (EFO_0000195), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2259', 'drugName': 'Goserelin', 'tradeNames_string': 'Zoladex', 'drugSynonyms_string': 'Goserelin, Goserelin acetate, ICI 118,630, ICI-118630', 'linkedDiseasesDrug_string': 'Uterine Fibroid (EFO_0000731), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Adenomyosis (EFO_1001757), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Premature Ovarian Insufficiency (HP_0008209), Male Breast Carcinoma (EFO_0006861), Endometriosis (EFO_0001065), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Invasive Lobular Carcinoma (EFO_0000553), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1921 | Q17 | What gene does the drug Antithrombin Alfa target? | The drug Antithrombin Alfa targets 2 genes: F10 and F2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%antithrombin alfa%" OR LOWER(tradeNames_string) LIKE "%antithrombin alfa%" OR LOWER(drugSynonyms_string) LIKE "%antithrombin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2886', 'drugName': 'Antithrombin Alfa', 'tradeNames_string': 'Atryn', 'drugSynonyms_string': 'Antithrombin (recombinant), Antithrombin alfa, Antithrombin iii,recombinant, Human anti-thrombin-iii, KW-3357', 'linkedDiseasesDrug_string': 'Disseminated Intravascular Coagulation (HP_0005521), Preeclampsia (EFO_0000668)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F10 (ENSG00000126218), F2 (ENSG00000180210)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2887', 'drugName': 'Antithrombin Alfa', 'tradeNames_string': 'Atryn', 'drugSynonyms_string': 'Antithrombin (recombinant), Antithrombin alfa, Antithrombin iii,recombinant, Human anti-thrombin-iii, KW-3357', 'linkedDiseasesDrug_string': 'Disseminated Intravascular Coagulation (HP_0005521), Preeclampsia (EFO_0000668)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F10 (ENSG00000126218), F2 (ENSG00000180210)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1963 | Q17 | What gene does the drug Bremelanotide target? | The drug Bremelanotide targets the gene MC4R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bremelanotide%" OR LOWER(tradeNames_string) LIKE "%bremelanotide%" OR LOWER(drugSynonyms_string) LIKE "%bremelanotide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_177', 'drugName': 'Bremelanotide Acetate', 'tradeNames_string': 'Vyleesi (autoinjector)', 'drugSynonyms_string': 'Bremelanotide acetate, PT 141, PT-141, Vyleesi', 'linkedDiseasesDrug_string': 'Sexual Dysfunction (EFO_0004714), Mental Or Behavioural Disorder (EFO_0000677)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MC4R (ENSG00000166603)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4990', 'drugName': 'Bremelanotide', 'tradeNames_string': 'Bremelanotide', 'drugSynonyms_string': 'Bremelanotide, PT-141, PT-141 FREE BASE', 'linkedDiseasesDrug_string': 'Nausea (HP_0002018), Sexual Dysfunction (EFO_0004714), Mental Or Behavioural Disorder (EFO_0000677)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MC4R (ENSG00000166603)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.214 | Q17 | What gene does the drug Brinzolamide target? | The drug Brinzolamide targets the gene CA2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brinzolamide%" OR LOWER(tradeNames_string) LIKE "%brinzolamide%" OR LOWER(drugSynonyms_string) LIKE "%brinzolamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3430', 'drugName': 'Brinzolamide', 'tradeNames_string': 'Azopt', 'drugSynonyms_string': 'AL-4862, Azopt, Brinzolamide, NSC-760050', 'linkedDiseasesDrug_string': 'Central Serous Retinopathy (EFO_0009784), Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA2 (ENSG00000104267)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.999 | Q17 | What gene does the drug Octreotide target? | The drug Octreotide targets 5 genes: SSTR5, SSTR3, SSTR4, SSTR1 and SSTR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%octreotide%" OR LOWER(tradeNames_string) LIKE "%octreotide%" OR LOWER(drugSynonyms_string) LIKE "%octreotide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_759', 'drugName': 'Octreotide Acetate', 'tradeNames_string': 'Bynfezia pen, Mycapssa, Octreotide acetate, Octreotide acetate (preservative free), Octreotide acetate preservative free, Sandostatin, Sandostatin lar', 'drugSynonyms_string': 'Octreolin, Octreotide (as acetate), Octreotide acetate, SMS 201-995 AC, SMS-201-995 AC, SMS-201995-AC', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Prader-Willi Syndrome (MONDO_0008300), Diarrhea (HP_0002014), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acromegaly (EFO_1001485), Diabetic Retinopathy (EFO_0003770), Lymphoma (EFO_0000574), Pituitary Tumor (MONDO_0017611), Metastasis (EFO_0009708), Neuroendocrine Neoplasm (EFO_1001901), Intestinal Obstruction (MONDO_0004565), Familial Hyperinsulinism (MONDO_0017182), Constipation (HP_0002019), Carcinoid Tumor (EFO_0004243), Liver Cancer (MONDO_0002691), Thymus Neoplasm (EFO_0002626), Carcinoid Syndrome (EFO_1000852), Neoplasm (EFO_0000616), Enteritis (MONDO_0043579)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR4 (ENSG00000132671), SSTR1 (ENSG00000139874), SSTR3 (ENSG00000278195)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5177', 'drugName': 'Octreotide', 'tradeNames_string': 'Sandostatin', 'drugSynonyms_string': 'Octreotide, SMS 201-995, SMS-201-995, SMS-995, SMS995', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Pancreatic Neuroendocrine Tumor (EFO_1000045), Infection (EFO_0000544), Islet Cell Tumor (EFO_0007331), Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Irritable Bowel Syndrome (EFO_0000555), Kidney Failure (EFO_1002048), Prader-Willi Syndrome (MONDO_0008300), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Diarrhea (HP_0002014), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acromegaly (EFO_1001485), Diabetic Retinopathy (EFO_0003770), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Lymphoma (EFO_0000574), Pituitary Tumor (MONDO_0017611), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Metastasis (EFO_0009708), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Intestinal Obstruction (MONDO_0004565), Familial Hyperinsulinism (MONDO_0017182), Carcinoid Tumor (EFO_0004243), Constipation (HP_0002019), Thymus Neoplasm (EFO_0002626), Liver Cancer (MONDO_0002691), Thymoma (EFO_1000581), Carcinoid Syndrome (EFO_1000852), Neoplasm (EFO_0000616), Enteritis (MONDO_0043579), Meningioma (MONDO_0016642), Gastrointestinal Hemorrhage (HP_0002239)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR4 (ENSG00000132671), SSTR1 (ENSG00000139874), SSTR3 (ENSG00000278195)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1269 | Q17 | What gene does the drug Desmopressin target? | The drug Desmopressin targets 3 genes: AVPR2, AVPR1A and AVPR1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desmopressin%" OR LOWER(tradeNames_string) LIKE "%desmopressin%" OR LOWER(drugSynonyms_string) LIKE "%desmopressin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1017', 'drugName': 'Desmopressin', 'tradeNames_string': '', 'drugSynonyms_string': 'Desmopressin, H01BA02, Ser-120, Ser120', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Intracerebral Hemorrhage (EFO_0005669), Breast Cancer (MONDO_0007254), Overactive Bladder (EFO_1000781), Hemorrhage (MP_0001914), Enuresis (MONDO_0024290), Central Diabetes Insipidus (HP_0000863), Renal Colic (EFO_1001412), Hypertension (EFO_0000537), Ecchymosis (HP_0031364), Leptospirosis (EFO_0007344), Nasal Congestion (HP_0001742), Diabetes Insipidus (MONDO_0004782), Von Willebrand Disease (Hereditary Or Acquired) (MONDO_0024574), Head Injury (EFO_0009505)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2993', 'drugName': 'Desmopressin Acetate', 'tradeNames_string': 'Concentraid, Ddavp, Ddavp (needs no refrigeration), Desmomelt, Desmopressin acetate, Desmopressin acetate (needs no refrigeration), Desmopressin acetate preservative free, Desmospray, Desmotabs, Minirin, Nocdurna, Noctiva, Nocutil, Noqdirna, Octim, Octostim, Presinex, Stimate, Stimate (needs no refrigeration)', 'drugSynonyms_string': 'Anhydrous desmopressin acetate, Desmopressin acetate, Desmopressin acetate anhydrous, Desmopressin acetate hydrate, Desmopressin acetate trihydrate', 'linkedDiseasesDrug_string': 'Intracerebral Hemorrhage (EFO_0005669), Enuresis (MONDO_0024290), Central Diabetes Insipidus (HP_0000863), Hemorrhage (MP_0001914), Hypertension (EFO_0000537), Ecchymosis (HP_0031364), Nasal Congestion (HP_0001742), Diabetes Insipidus (MONDO_0004782), Von Willebrand Disease (Hereditary Or Acquired) (MONDO_0024574), Head Injury (EFO_0009505)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.592 | Q17 | What gene does the drug Moclobemide target? | The drug Moclobemide targets the gene MAOA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moclobemide%" OR LOWER(tradeNames_string) LIKE "%moclobemide%" OR LOWER(drugSynonyms_string) LIKE "%moclobemide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6369', 'drugName': 'Moclobemide', 'tradeNames_string': 'Manerix', 'drugSynonyms_string': 'Aurorix, GNF-PF-695, Moclobemide, RO 11-1163/000, RO-111163000', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Drug Dependence (EFO_0003890), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOA (ENSG00000189221)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1391 | Q17 | What gene does the drug Flurbiprofen target? | The drug Flurbiprofen targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flurbiprofen%" OR LOWER(tradeNames_string) LIKE "%flurbiprofen%" OR LOWER(drugSynonyms_string) LIKE "%flurbiprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2737', 'drugName': 'Flurbiprofen Sodium', 'tradeNames_string': 'Ansaid, Flurbiprofen sodium, Occufen, Ocufen, Zepolas', 'drugSynonyms_string': 'Flurbiprofen sodium, Flurbiprofen sodium anhydrous, Flurbiprofen sodium dihydrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5775', 'drugName': 'Flurbiprofen', 'tradeNames_string': 'Ansaid, Cebutid, Flurbiprofen, Froben, Froben sr, Strefen, Transact', 'drugSynonyms_string': 'BTS 18,322, BTS-18322, Flubiprofen, Flurbiprofen, NSC-757037, Ocufen, U-27,182, U-27182', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Pharyngitis (MONDO_0002258), Hiv Infection (EFO_0000764), Arthralgia (HP_0002829), Anemia (Phenotype) (EFO_0004272), Pain (EFO_0003843), Eye Inflammation (EFO_0005752), Miosis (HP_0000616), Mitochondrial Disease (MONDO_0044970), Periodontitis (EFO_0000649), Low Back Pain (HP_0003419), Rheumatoid Arthritis (EFO_0000685), Type 2 Diabetes Mellitus (MONDO_0005148), Myalgia (HP_0003326)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5008', 'drugName': 'Esflurbiprofen', 'tradeNames_string': '', 'drugSynonyms_string': 'BTS 24332, BTS-24332, Esflurbiprofen, Flurbiprofen, (s)-', 'linkedDiseasesDrug_string': 'Sprain (EFO_0009582), Arthralgia (HP_0002829), Myalgia (HP_0003326)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2667', 'drugName': 'Tarenflurbil', 'tradeNames_string': 'Flurizan', 'drugSynonyms_string': 'E-7869, Flurbiprofen, (r)-, MPC-7869, R-flurbiprofen, Tarenflurbil', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Prostate Cancer (MONDO_0008315), Dementia (HP_0000726)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'APH1A (ENSG00000117362), PSENEN (ENSG00000205155), APH1B (ENSG00000138613), PSEN1 (ENSG00000080815), NCSTN (ENSG00000162736), PSEN2 (ENSG00000143801)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1450 | Q17 | What gene does the drug Albuterol Sulfate target? | The drug Albuterol Sulfate targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%albuterol sulfate%" OR LOWER(tradeNames_string) LIKE "%albuterol sulfate%" OR LOWER(drugSynonyms_string) LIKE "%albuterol sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6278', 'drugName': 'Albuterol Sulfate', 'tradeNames_string': 'Accuneb, Albuterol sulfate, Proair, Proair digihaler, Proair hfa, Proair respiclick, Proventil, Proventil-hfa, Ventolin, Ventolin hfa, Ventolin rotacaps, Volmax, Vospire er', 'drugSynonyms_string': 'Albuterol sulfate, Albuterol sulphate, Buventol, Ecovent, Hexotonal, Loftan, NSC-289928, R03AC02, R03CC02, SCH 13949W SULFATE, SCH-13949W SULFATE, Salamol, Salbumol, Salbutamol (as sulfate), Salbutamol sulfate, Salbutamol sulphate, Salbutamoli sulfas, Sch 13949w sulphate, Sch-13949w sulphate, Sulbutamol (as sulphate), Sultanol, Torpex, Venetlin, Ventilastin, Vospire', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Lung Disease (EFO_0003818)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.279 | Q17 | What gene does the drug Divalproex Sodium target? | The drug Divalproex Sodium targets the gene ALDH5A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%divalproex sodium%" OR LOWER(tradeNames_string) LIKE "%divalproex sodium%" OR LOWER(drugSynonyms_string) LIKE "%divalproex sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5683', 'drugName': 'Divalproex Sodium', 'tradeNames_string': 'Depakote, Depakote cp, Depakote er, Divalproex sodium', 'drugSynonyms_string': 'ABBOTT 50711, ABBOTT-50711, Divalproex, Divalproex sodium, Semisodium valproate, Valproate semisodium, Valproic acid sodium salt (2:1)', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Migraine Disorder (MONDO_0005277), Focal-Onset Seizure (HP_0007359), Post-Traumatic Stress Disorder (EFO_0001358), Mood Disorder (EFO_0004247), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Epilepsy (EFO_0000474), Seizure (HP_0001250), Complex Partial Epilepsy (EFO_1000877), Oppositional Defiant Disorder (HP_0010865), Bipolar Disorder (MONDO_0004985), Systemic Scleroderma (EFO_0000717), Alcohol Dependence (MONDO_0007079), Unipolar Depression (EFO_0003761), Neoplasm (EFO_0000616), Generalized Non-Motor (Absence) Seizure (HP_0002121), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALDH5A1 (ENSG00000112294)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1507 | Q17 | What gene does the drug Quinidine Polygalacturonate target? | The drug Quinidine Polygalacturonate targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quinidine polygalacturonate%" OR LOWER(tradeNames_string) LIKE "%quinidine polygalacturonate%" OR LOWER(drugSynonyms_string) LIKE "%quinidine polygalacturonate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_154', 'drugName': 'Quinidine Polygalacturonate', 'tradeNames_string': 'Cardioquin', 'drugSynonyms_string': 'Galactoquin, Naticardina, Quinidine polygalacturonate', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1328 | Q17 | What gene does the drug Azd1446 target? | The drug Azd1446 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CHRNA4 and CHRNB2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd1446%" OR LOWER(tradeNames_string) LIKE "%azd1446%" OR LOWER(drugSynonyms_string) LIKE "%azd1446%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4875', 'drugName': 'Azd1446', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-1446, AZD1446 HCL, Azd 1446, Azd1446, Azd1446 free base, TC-6683, TC6683, TC6683 HCL', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1271 | Q17 | What gene does the drug Dihydrocodeine target? | The drug Dihydrocodeine targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dihydrocodeine%" OR LOWER(tradeNames_string) LIKE "%dihydrocodeine%" OR LOWER(drugSynonyms_string) LIKE "%dihydrocodeine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2341', 'drugName': 'Dihydrocodeine', 'tradeNames_string': '', 'drugSynonyms_string': '.alpha.-hydrocodol, 8,14-dihydroneopine, Codhydrine, Dehacodin, Dh-codeine, Dihydrocodeine, IDS-ND-008(SECT.2), NSC-231319, Novicondin, Rapacodin, Remedacen', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4198', 'drugName': 'Dihydrocodeine Bitartrate', 'tradeNames_string': '', 'drugSynonyms_string': 'Codeine, dihydro-, tartrate (1:1), DF 118, DF-118, Dihydrocodeine bitartrate, Dihydrocodeine bitartrate cii, Dihydrocodeine hydrogen tartrate, Dihydrocodeine phosphate, Dihydrocodeine tartrate, Dihydroneopine, Drocode, NSC-117857', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1820 | Q17 | What gene does the drug Desoxycorticosterone Pivalate target? | The drug Desoxycorticosterone Pivalate targets the gene NR3C2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desoxycorticosterone pivalate%" OR LOWER(tradeNames_string) LIKE "%desoxycorticosterone pivalate%" OR LOWER(drugSynonyms_string) LIKE "%desoxycorticosterone pivalate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3356', 'drugName': 'Desoxycorticosterone Pivalate', 'tradeNames_string': 'Percorten', 'drugSynonyms_string': 'Desoxycorticosterone pivalate, Desoxycorticosterone trimethylacetate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.273 | Q17 | What gene does the drug Dicumarol target? | The drug Dicumarol targets the gene VKORC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dicumarol%" OR LOWER(tradeNames_string) LIKE "%dicumarol%" OR LOWER(drugSynonyms_string) LIKE "%dicumarol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1631', 'drugName': 'Dicumarol', 'tradeNames_string': 'Dicumarol', 'drugSynonyms_string': 'Bishydroxycoumarin, Dicoumarol, Dicoumarolum, Dicumarol, NSC-17860, NSC-221570, NSC-41834', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419)', 'yearOfFirstApproval': 1944, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VKORC1 (ENSG00000167397)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1863 | Q17 | What gene does the drug Risperidone target? | The drug Risperidone targets 3 genes: HTR2C, HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_string) LIKE "%risperidone%" OR LOWER(drugSynonyms_string) LIKE "%risperidone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3866', 'drugName': 'Risperidone', 'tradeNames_string': 'Perseris kit, Risperdal, Risperdal Consta Long Acting, Risperdal M, Risperdal M-Tab, Risperdal consta, Risperdal quicklet, Risperidone', 'drugSynonyms_string': 'LY-03004, LY03004, N05AX08, NSC-759895, Perseris, R 64 766, R-64,766, R-64-766, R-64766, RCN-3028, RCN3028, Risperidone', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizotypal Personality Disorder (MONDO_0001087), Intellectual Disability (HP_0001249), Conduct Disorder (EFO_0004216), Drug-Induced Dyskinesia (EFO_1000904), Vascular Dementia (EFO_0004718), Post-Traumatic Stress Disorder (EFO_0001358), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Oppositional Defiant Disorder (HP_0010865), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Developmental Disability (EFO_0003852), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3643', 'drugName': 'Paliperidone', 'tradeNames_string': 'Invega, Paliperidone, Trevicta, Xeplion', 'drugSynonyms_string': '9-hydroxyrisperidone, NSC-759623, Paliperidone, R-76477, RO-76477, RO76477, Risperidone impurity, 9-hydroxyrisperidone-', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Psychosis (EFO_0005407), Obsessive-Compulsive Disorder (EFO_0004242), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3644', 'drugName': 'Paliperidone', 'tradeNames_string': 'Invega, Paliperidone, Trevicta, Xeplion', 'drugSynonyms_string': '9-hydroxyrisperidone, NSC-759623, Paliperidone, R-76477, RO-76477, RO76477, Risperidone impurity, 9-hydroxyrisperidone-', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Psychosis (EFO_0005407), Obsessive-Compulsive Disorder (EFO_0004242), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3867', 'drugName': 'Risperidone', 'tradeNames_string': 'Perseris kit, Risperdal, Risperdal Consta Long Acting, Risperdal M, Risperdal M-Tab, Risperdal consta, Risperdal quicklet, Risperidone', 'drugSynonyms_string': 'LY-03004, LY03004, N05AX08, NSC-759895, Perseris, R 64 766, R-64,766, R-64-766, R-64766, RCN-3028, RCN3028, Risperidone', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizotypal Personality Disorder (MONDO_0001087), Intellectual Disability (HP_0001249), Conduct Disorder (EFO_0004216), Drug-Induced Dyskinesia (EFO_1000904), Vascular Dementia (EFO_0004718), Post-Traumatic Stress Disorder (EFO_0001358), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Oppositional Defiant Disorder (HP_0010865), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Developmental Disability (EFO_0003852), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3865', 'drugName': 'Risperidone', 'tradeNames_string': 'Perseris kit, Risperdal, Risperdal Consta Long Acting, Risperdal M, Risperdal M-Tab, Risperdal consta, Risperdal quicklet, Risperidone', 'drugSynonyms_string': 'LY-03004, LY03004, N05AX08, NSC-759895, Perseris, R 64 766, R-64,766, R-64-766, R-64766, RCN-3028, RCN3028, Risperidone', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizotypal Personality Disorder (MONDO_0001087), Intellectual Disability (HP_0001249), Conduct Disorder (EFO_0004216), Drug-Induced Dyskinesia (EFO_1000904), Vascular Dementia (EFO_0004718), Post-Traumatic Stress Disorder (EFO_0001358), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Oppositional Defiant Disorder (HP_0010865), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Developmental Disability (EFO_0003852), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.578 | Q17 | What gene does the drug Anisotropine Methylbromide target? | The drug Anisotropine Methylbromide targets 2 genes: CHRM3 and CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anisotropine methylbromide%" OR LOWER(tradeNames_string) LIKE "%anisotropine methylbromide%" OR LOWER(drugSynonyms_string) LIKE "%anisotropine methylbromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6145', 'drugName': 'Anisotropine Methylbromide', 'tradeNames_string': 'Anisotropine methylbromide, Valpin, Valpin 50', 'drugSynonyms_string': 'Anisotropine methylbromide, Methyloctatropine bromide, Octatropine methylbromide, Octatropone bromide, Octotropine methylbromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6146', 'drugName': 'Anisotropine Methylbromide', 'tradeNames_string': 'Anisotropine methylbromide, Valpin, Valpin 50', 'drugSynonyms_string': 'Anisotropine methylbromide, Methyloctatropine bromide, Octatropine methylbromide, Octatropone bromide, Octotropine methylbromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.638 | Q17 | What gene does the drug Sx-682 target? | The drug Sx-682 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CXCR1 and CXCR2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sx-682%" OR LOWER(tradeNames_string) LIKE "%sx-682%" OR LOWER(drugSynonyms_string) LIKE "%sx-682%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5770', 'drugName': 'Sx-682', 'tradeNames_string': '', 'drugSynonyms_string': 'SX-682, Sx-682', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCR2 (ENSG00000180871), CXCR1 (ENSG00000163464)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.713 | Q17 | What gene does the drug Ethylestrenol target? | The drug Ethylestrenol targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethylestrenol%" OR LOWER(tradeNames_string) LIKE "%ethylestrenol%" OR LOWER(drugSynonyms_string) LIKE "%ethylestrenol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3566', 'drugName': 'Ethylestrenol', 'tradeNames_string': 'Maxibolin', 'drugSynonyms_string': 'Durabolin-o, Duraboral, Ethylestrenol, Ethylnandrol, Ethyloestrenol, NSC-37726, Orabolin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1529 | Q17 | What gene does the drug Pindolol target? | The drug Pindolol targets 2 genes: ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pindolol%" OR LOWER(tradeNames_string) LIKE "%pindolol%" OR LOWER(drugSynonyms_string) LIKE "%pindolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4457', 'drugName': 'Pindolol', 'tradeNames_string': 'Betadren, Pindolol, Visken', 'drugSynonyms_string': '(rs)-pindolol, Apo-pindol, Betapindol, Blocklin-l, Calvisken, Carvisken, Decreten, Dl-lb-46, Dl-pindolol, Durapindol, Glauco-visken, LB-46, NSC-757276, Pectobloc, Pinbetol, Pindolol, Prinodolol, Pynastin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4458', 'drugName': 'Pindolol', 'tradeNames_string': 'Betadren, Pindolol, Visken', 'drugSynonyms_string': '(rs)-pindolol, Apo-pindol, Betapindol, Blocklin-l, Calvisken, Carvisken, Decreten, Dl-lb-46, Dl-pindolol, Durapindol, Glauco-visken, LB-46, NSC-757276, Pectobloc, Pinbetol, Pindolol, Prinodolol, Pynastin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.627 | Q17 | What gene does the drug Phenmetrazine Hydrochloride target? | The drug Phenmetrazine Hydrochloride targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenmetrazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%phenmetrazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%phenmetrazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4238', 'drugName': 'Phenmetrazine Hydrochloride', 'tradeNames_string': 'Preludin', 'drugSynonyms_string': 'NSC-405728, Phenmetraline hydrochloride, Phenmetrazine chloride, Phenmetrazine hcl, Phenmetrazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4239', 'drugName': 'Phenmetrazine Hydrochloride', 'tradeNames_string': 'Preludin', 'drugSynonyms_string': 'NSC-405728, Phenmetraline hydrochloride, Phenmetrazine chloride, Phenmetrazine hcl, Phenmetrazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1991 | Q17 | What gene does the drug Dronabinol target? | The drug Dronabinol targets the gene CNR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dronabinol%" OR LOWER(tradeNames_string) LIKE "%dronabinol%" OR LOWER(drugSynonyms_string) LIKE "%dronabinol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3038', 'drugName': 'Dronabinol', 'tradeNames_string': 'Dronabinol, Marinol, Syndros', 'drugSynonyms_string': '.delta.-9-tetrahydrocannabinol, .delta.1-thc, .delta.9-tetrahydrocannabinol, .delta.9-thc, ABBOTT 40566, ABBOTT-40566, Delta-9-tetrahydrocannabinol, Delta-9-thc, Dronabinol, J882F, NSC-134454, QCD 84924, QCD-84924, SP 104, SP-104, Tetrahydrocannabinol, Tetrahydrocannabinols (-)-trans-.delta.9-form', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Multiple Sclerosis (MONDO_0005301), Migraine Without Aura (MONDO_0100431), Pain (EFO_0003843), Tourette Syndrome (EFO_0004895), Irritable Bowel Syndrome (EFO_0000555), Cannabis Dependence (EFO_0007191), Anorexia Nervosa (MONDO_0005351), Post-Traumatic Stress Disorder (EFO_0001358), Migraine With Aura (MONDO_0005475), Psoriatic Arthritis (EFO_0003778), Osteoarthritis, Knee (EFO_0004616), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Arthropathy (HP_0003040), Alcohol Drinking (EFO_0004329), Drug Dependence (EFO_0003890), Sickle Cell Anemia (MONDO_0011382), Hair-Pulling (HP_0012167), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090), Obstructive Sleep Apnea (EFO_0003918), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Amyotrophic Lateral Sclerosis (MONDO_0004976), Osteoarthritis (MONDO_0005178), Nausea And Vomiting (HP_0002017), Essential Tremor (EFO_0003108), Chronic Pain (HP_0012532), Torticollis (HP_0000473), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia (HP_0002039)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CNR1 (ENSG00000118432)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.813 | Q17 | What gene does the drug Dextroamphetamine Saccharate target? | The drug Dextroamphetamine Saccharate targets 3 genes: SLC6A2, SLC6A3 and SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dextroamphetamine saccharate%" OR LOWER(tradeNames_string) LIKE "%dextroamphetamine saccharate%" OR LOWER(drugSynonyms_string) LIKE "%dextroamphetamine saccharate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_983', 'drugName': 'Dextroamphetamine Saccharate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine saccharate, Dexamfetamine hemisaccharate, Dexamfetamine saccharate, Dexamfetaphine saccharate, Dextroamphetamine saccharate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_984', 'drugName': 'Dextroamphetamine Saccharate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine saccharate, Dexamfetamine hemisaccharate, Dexamfetamine saccharate, Dexamfetaphine saccharate, Dextroamphetamine saccharate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_985', 'drugName': 'Dextroamphetamine Saccharate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine saccharate, Dexamfetamine hemisaccharate, Dexamfetamine saccharate, Dexamfetaphine saccharate, Dextroamphetamine saccharate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.309 | Q17 | What gene does the drug Fingolimod Hydrochloride target? | The drug Fingolimod Hydrochloride targets 5 genes: S1PR3, S1PR4, S1PR5, S1PR1 and S1PR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fingolimod hydrochloride%" OR LOWER(tradeNames_string) LIKE "%fingolimod hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%fingolimod hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4765', 'drugName': 'Fingolimod Hydrochloride', 'tradeNames_string': 'Gilenya', 'drugSynonyms_string': 'FTY-720 HYDROCHLORIDE, FTY720, FTY720 HYDROCHLORIDE, Fingolimod, Fingolimod (as hydrochloride), Fingolimod hcl, Fingolimod hydrochlorid, Fingolimod hydrochloride, Gilenia', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Breast Carcinoma (EFO_0000305), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.550 | Q17 | What gene does the drug Tozasertib target? | The drug Tozasertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: AURKB, AURKC and AURKA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tozasertib%" OR LOWER(tradeNames_string) LIKE "%tozasertib%" OR LOWER(drugSynonyms_string) LIKE "%tozasertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2881', 'drugName': 'Tozasertib', 'tradeNames_string': '', 'drugSynonyms_string': 'MK-045, MK-0457, Tozasertib, VX-68, VX-680', 'linkedDiseasesDrug_string': 'Lymphoid Leukemia (EFO_0004289), Cancer (MONDO_0004992), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Lymphoblastic Leukemia (EFO_0000220), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999), AURKC (ENSG00000105146), AURKA (ENSG00000087586)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1606 | Q17 | What gene does the drug Aldafermin target? | The drug Aldafermin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: FGF1, FGFR4 and KLB | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aldafermin%" OR LOWER(tradeNames_string) LIKE "%aldafermin%" OR LOWER(drugSynonyms_string) LIKE "%aldafermin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_570', 'drugName': 'Aldafermin', 'tradeNames_string': '', 'drugSynonyms_string': 'Aldafermin, NGM-282, NGM282, Ngm282', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Liver Disease (EFO_0001421), Non-Alcoholic Steatohepatitis (EFO_1001249), Kidney Disease (EFO_0003086), Constipation (HP_0002019), Sclerosing Cholangitis (EFO_0004268), Primary Biliary Cirrhosis (EFO_1001486)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR4 (ENSG00000160867), KLB (ENSG00000134962), FGF1 (ENSG00000113578)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_571', 'drugName': 'Aldafermin', 'tradeNames_string': '', 'drugSynonyms_string': 'Aldafermin, NGM-282, NGM282, Ngm282', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Liver Disease (EFO_0001421), Non-Alcoholic Steatohepatitis (EFO_1001249), Kidney Disease (EFO_0003086), Constipation (HP_0002019), Sclerosing Cholangitis (EFO_0004268), Primary Biliary Cirrhosis (EFO_1001486)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR4 (ENSG00000160867), KLB (ENSG00000134962), FGF1 (ENSG00000113578)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1743 | Q17 | What gene does the drug Dihydroergotamine target? | The drug Dihydroergotamine targets the gene HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dihydroergotamine%" OR LOWER(tradeNames_string) LIKE "%dihydroergotamine%" OR LOWER(drugSynonyms_string) LIKE "%dihydroergotamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6027', 'drugName': 'Dihydroergotamine', 'tradeNames_string': '', 'drugSynonyms_string': '9,10-dihydroergotamine, Dihydroergotamine, MAP-0004, MAP0004, Neomigran', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Disorder (MONDO_0005277), Migraine Without Aura (MONDO_0100431)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5316', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_string': 'D.h.e. 45, Diergo, Dihydergot, Dihydroergotamine mesylate, Tonopan, Trudhesa', 'drugSynonyms_string': 'DHE-45, Dihydroergotamine Methanesulfonate, Dihydroergotamine mesilate, Dihydroergotamine mesylate, Dihydroergotamine methanesulfonate, Migranal, NSC-759848', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.50 | Q17 | What gene does the drug Mk-2201 target? | The drug Mk-2201 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: AKT2, AKT1 and AKT3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mk-2201%" OR LOWER(tradeNames_string) LIKE "%mk-2201%" OR LOWER(drugSynonyms_string) LIKE "%mk-2201%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1380', 'drugName': 'Mk-2201', 'tradeNames_string': '', 'drugSynonyms_string': 'Mk-2201', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AKT2 (ENSG00000105221), AKT3 (ENSG00000117020), AKT1 (ENSG00000142208)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1089 | Q17 | What gene does the drug Tamoxifen target? | The drug Tamoxifen targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tamoxifen%" OR LOWER(tradeNames_string) LIKE "%tamoxifen%" OR LOWER(drugSynonyms_string) LIKE "%tamoxifen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4005', 'drugName': 'Tamoxifen', 'tradeNames_string': '', 'drugSynonyms_string': 'ICI-46474, ICI-47699, Mammaton, NSC-727681, Nolvadex, Novaldex, Soltamox, Tamoplex, Tamoxifen', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Male Infertility (EFO_0004248), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Igg4-Related Retroperitoneal Fibrosis (MONDO_0018848), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Cervical Adenocarcinoma (EFO_0001416), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Hypertension (EFO_0000537), Male Breast Carcinoma (EFO_0006861), Metastasis (EFO_0009708), Endometrial Carcinoma (EFO_1001512), Inflammatory Breast Carcinoma (EFO_1000984), Central Nervous System Neoplasm (EFO_1000158), Neuroendocrine Neoplasm (EFO_1001901), Menopause (EFO_0003922), Duchenne Muscular Dystrophy (MONDO_0010679), Infertility (EFO_0000545), Adenoma (EFO_0000232), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Chronic Hepatitis C Virus Infection (EFO_0004220), Bipolar Disorder (MONDO_0004985), Glioma (EFO_0005543), Breast Ductal Carcinoma In Situ (EFO_0000432), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Hyperplasia (EFO_0000536), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Amyotrophic Lateral Sclerosis (MONDO_0004976), Urinary Bladder Cancer (MONDO_0001187), Gynecomastia (HP_0000771), Desmoid-Type Fibromatosis (EFO_0009907), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1083', 'drugName': 'Toremifene', 'tradeNames_string': '', 'drugSynonyms_string': 'Acapodene, Chlortamoxifen, Farestone, GTX-006, J33.157K, Toremifene, Toremiphene', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Osteoporosis (EFO_0003882), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Covid-19 (MONDO_0100096), Mastodynia (EFO_1001366), Prostate Intraepithelial Neoplasia (EFO_0002621), Breast Carcinoma (EFO_0000305), Bone Fracture (EFO_0003931), Ovarian Cancer (MONDO_0008170), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5201', 'drugName': 'Tamoxifen Citrate', 'tradeNames_string': 'Emblon, Fentamox 10, Fentamox 20, Kentadex, Kessar, Kessar 10, Kessar 20, Noltam, Nolvadex, Nolvadex d, Nolvadex fte, Oestrifen-10, Oestrifen-20, Oestrifen-40, Soltamox, Tamofen, Tamoxifen citrate, Zynoplex', 'drugSynonyms_string': 'I.C.I.46474 CITRATE, ICI 46,474, ICI-46474, Kessar, NSC-180973, NSC-757345, Nourytam, Tamofene, Tamoxifen citrate, Tamoxifeni citras, Tomaxasta, Zemide, Zitazonium', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Male Infertility (EFO_0004248), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Igg4-Related Retroperitoneal Fibrosis (MONDO_0018848), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Cervical Adenocarcinoma (EFO_0001416), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Hypertension (EFO_0000537), Male Breast Carcinoma (EFO_0006861), Metastasis (EFO_0009708), Endometrial Carcinoma (EFO_1001512), Inflammatory Breast Carcinoma (EFO_1000984), Central Nervous System Neoplasm (EFO_1000158), Neuroendocrine Neoplasm (EFO_1001901), Menopause (EFO_0003922), Duchenne Muscular Dystrophy (MONDO_0010679), Infertility (EFO_0000545), Adenoma (EFO_0000232), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Chronic Hepatitis C Virus Infection (EFO_0004220), Bipolar Disorder (MONDO_0004985), Glioma (EFO_0005543), Breast Ductal Carcinoma In Situ (EFO_0000432), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Hyperplasia (EFO_0000536), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Amyotrophic Lateral Sclerosis (MONDO_0004976), Urinary Bladder Cancer (MONDO_0001187), Gynecomastia (HP_0000771), Desmoid-Type Fibromatosis (EFO_0009907), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5487', 'drugName': 'Droloxifene', 'tradeNames_string': '', 'drugSynonyms_string': '3-hydroxytamoxifen, Droloxifene, E-Droloxifene, FK-435, Fk-435, K-060, K-21060E, K060, K060E', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5111', 'drugName': 'Afimoxifene', 'tradeNames_string': 'Tamogel', 'drugSynonyms_string': '4-Hydroxytamoxifen, 4-OHT, Afimoxifene', 'linkedDiseasesDrug_string': 'Breast Ductal Carcinoma In Situ (EFO_0000432), Mastodynia (EFO_1001366), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESRRG (ENSG00000196482), ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5112', 'drugName': 'Afimoxifene', 'tradeNames_string': 'Tamogel', 'drugSynonyms_string': '4-Hydroxytamoxifen, 4-OHT, Afimoxifene', 'linkedDiseasesDrug_string': 'Breast Ductal Carcinoma In Situ (EFO_0000432), Mastodynia (EFO_1001366), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESRRG (ENSG00000196482), ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1674 | Q17 | What gene does the drug Diazoxide target? | The drug Diazoxide targets 2 genes: KCNJ11 and KCNJ8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diazoxide%" OR LOWER(tradeNames_string) LIKE "%diazoxide%" OR LOWER(drugSynonyms_string) LIKE "%diazoxide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1171', 'drugName': 'Diazoxide', 'tradeNames_string': 'Diazoxide, Eudemine, Eudimine, Hyperstat, Mutabase, Proglycem', 'drugSynonyms_string': 'Diazoxide, Diazoxidum, Eudemine injection, Hypertonalum, NSC-64198, NSC-76130, SCH 6783, SCH-6783, SRG 95213, SRG-95213', 'linkedDiseasesDrug_string': 'Hypertriglyceridemia (EFO_0004211), Hypertension (EFO_0000537), Obesity (EFO_0001073), Prader-Willi Syndrome (MONDO_0008300), Depressive Disorder (MONDO_0002050), Pancreatic Insulinoma (MONDO_0024677), Hypoglycemia (HP_0001943), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperinsulinism (MONDO_0002177)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), KCNJ8 (ENSG00000121361)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1172', 'drugName': 'Diazoxide', 'tradeNames_string': 'Diazoxide, Eudemine, Eudimine, Hyperstat, Mutabase, Proglycem', 'drugSynonyms_string': 'Diazoxide, Diazoxidum, Eudemine injection, Hypertonalum, NSC-64198, NSC-76130, SCH 6783, SCH-6783, SRG 95213, SRG-95213', 'linkedDiseasesDrug_string': 'Hypertriglyceridemia (EFO_0004211), Hypertension (EFO_0000537), Obesity (EFO_0001073), Prader-Willi Syndrome (MONDO_0008300), Depressive Disorder (MONDO_0002050), Pancreatic Insulinoma (MONDO_0024677), Hypoglycemia (HP_0001943), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperinsulinism (MONDO_0002177)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), KCNJ8 (ENSG00000121361)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1697 | Q17 | What gene does the drug Estriol target? | The drug Estriol targets 2 genes: ESR2 and ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estriol%" OR LOWER(tradeNames_string) LIKE "%estriol%" OR LOWER(drugSynonyms_string) LIKE "%estriol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_223', 'drugName': 'Estriol', 'tradeNames_string': 'Gynest, Ortho-gynest, Ovestin, Theelol', 'drugSynonyms_string': '16.ALPHA.-HYDROXYESTRADIOL, 16.alpha.,17.beta.-estriol, Aacifemine, Colpogyn, Estriol, Estriol acetate benzoate, Estriol propionate, Estriol succinate, Incurin, NSC-12169, Oestriol, Trihydroxyestrin', 'linkedDiseasesDrug_string': 'Secondary Progressive Multiple Sclerosis (EFO_0008522), Atrophic Vaginitis (EFO_1001271), Menopause (EFO_0003922), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Pregnancy (EFO_0002950), Primary Progressive Multiple Sclerosis (EFO_0008520)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4568', 'drugName': 'Estetrol', 'tradeNames_string': '', 'drugSynonyms_string': '15.alpha.-hydroxyestriol, E-4, E4, Estetrol, Estetrol (anhydrous), Estetrol (hydrous), Estetrol anhydrous, Estetrol hydrate, Estetrol monohydrate', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Menopause (EFO_0003922), Covid-19 (MONDO_0100096), Pregnancy (EFO_0002950), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.686 | Q17 | What gene does the drug Ly2590443 target? | The drug Ly2590443 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ly2590443%" OR LOWER(tradeNames_string) LIKE "%ly2590443%" OR LOWER(drugSynonyms_string) LIKE "%ly2590443%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3587', 'drugName': 'Ly2590443', 'tradeNames_string': '', 'drugSynonyms_string': 'Ly2590443', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR7 (ENSG00000148680)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1485 | Q17 | What gene does the drug Canagliflozin target? | The drug Canagliflozin targets the gene SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%canagliflozin%" OR LOWER(tradeNames_string) LIKE "%canagliflozin%" OR LOWER(drugSynonyms_string) LIKE "%canagliflozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4559', 'drugName': 'Canagliflozin', 'tradeNames_string': 'Invokana', 'drugSynonyms_string': 'Canagliflozin, Canagliflozin hemihydrate, Canagliflozin hydrate, JNJ-24831754-ZAE, JNJ-28431754, JNJ-28431754-AAA, TA-7284', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Polycystic Ovary Syndrome (EFO_0000660), Breast Cancer (MONDO_0007254), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Obesity (EFO_0001073), Renal Insufficiency (HP_0000083), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6346', 'drugName': 'Canagliflozin', 'tradeNames_string': '', 'drugSynonyms_string': 'Canagliflozin, JNJ-24831754-ZAE, JNJ-28431754, JNJ-28431754-AAA, TA-7284', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Polycystic Ovary Syndrome (EFO_0000660), Breast Cancer (MONDO_0007254), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Obesity (EFO_0001073), Renal Insufficiency (HP_0000083), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1455 | Q17 | What gene does the drug Tesaglitazar target? | The drug Tesaglitazar is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: PPARG and PPARA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tesaglitazar%" OR LOWER(tradeNames_string) LIKE "%tesaglitazar%" OR LOWER(drugSynonyms_string) LIKE "%tesaglitazar%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5001', 'drugName': 'Tesaglitazar', 'tradeNames_string': 'Galida', 'drugSynonyms_string': 'AR-H-039242, AR-H039242XX, AZ-242, Az-242, BR-44608, Tesaglitazar', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARA (ENSG00000186951), PPARG (ENSG00000132170)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5002', 'drugName': 'Tesaglitazar', 'tradeNames_string': 'Galida', 'drugSynonyms_string': 'AR-H-039242, AR-H039242XX, AZ-242, Az-242, BR-44608, Tesaglitazar', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARA (ENSG00000186951), PPARG (ENSG00000132170)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1486 | Q17 | What gene does the drug Vinorelbine Tartrate target? | The drug Vinorelbine Tartrate targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vinorelbine tartrate%" OR LOWER(tradeNames_string) LIKE "%vinorelbine tartrate%" OR LOWER(drugSynonyms_string) LIKE "%vinorelbine tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'tradeNames_string': 'Navelbine, Vinorelbine tartrate', 'drugSynonyms_string': 'Liposomal vinorelbine tartrate, TLC-178, TLC178, Vinorelbine (as tartrate), Vinorelbine Ditartarate, Vinorelbine ditartrate, Vinorelbine liposomal, Vinorelbine tartrate, Vinorelbine tartrate (1:2)', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Non-Hodgkins Lymphoma (EFO_0005952), Vaginal Cancer (MONDO_0001402), Endometrial Cancer (MONDO_0011962), Malignant Colon Neoplasm (MONDO_0021063), Breast Neoplasm (EFO_0003869), Cervical Adenocarcinoma (EFO_0001416), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Embryonal Rhabdomyosarcoma (EFO_0000437), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Central Nervous System Neoplasm (EFO_1000158), Lung Adenocarcinoma (EFO_0000571), Mesothelioma (EFO_0000588), Alveolar Rhabdomyosarcoma (EFO_0000248), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1292 | Q17 | What gene does the drug Celecoxib target? | The drug Celecoxib targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_string) LIKE "%celecoxib%" OR LOWER(drugSynonyms_string) LIKE "%celecoxib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5116', 'drugName': 'Celecoxib', 'tradeNames_string': 'Celebra, Celebrex, Celecoxib, Elyxyb, Onsenal', 'drugSynonyms_string': 'Celecoxib, DFN-15, DFN15, NSC-719627, NSC-758624, SC-58635', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Familial Adenomatous Polyposis (Orphanet_733), Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Migraine Disorder (MONDO_0005277), Peptic Ulcer Disease (MONDO_0004247), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Graves Ophthalmopathy (EFO_1001466), Intracerebral Hemorrhage (EFO_0005669), Lymphangioleiomyomatosis (MONDO_0011705), Hand-Foot Syndrome (EFO_1001893), Spinal Muscular Atrophy (EFO_0008525), Hypertension (EFO_0000537), Neuropathic Pain (EFO_0005762), Obsessive-Compulsive Disorder (EFO_0004242), Benign Prostatic Hyperplasia (EFO_0000284), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Gout (EFO_0004274), Monoclonal Gammopathy (EFO_0000203), Lung Cancer (MONDO_0008903), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Spondylitis (MONDO_0003937), Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Colorectal Carcinoma (EFO_1001951), Breast Carcinoma In Situ (MONDO_0004658), Hepatocellular Carcinoma (EFO_0000182), Peptic Ulcer (HP_0004398), Memory Impairment (EFO_0001072), Pharyngitis (MONDO_0002258), Stroke (EFO_0000712), Actinic Keratosis (EFO_0002496), Influenza (EFO_0007328), Rectum Cancer (EFO_1000657), Osteoarthritis (MONDO_0005178), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Low Back Pain (HP_0003419), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Wilson Disease (MONDO_0010200), Mouth Neoplasm (EFO_0003868), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Preeclampsia (EFO_0000668), Postpartum Depression (EFO_0007453), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Juvenile Idiopathic Arthritis (EFO_0002609), Rotator Cuff Tear (EFO_1001250), Osteoarthritis, Knee (EFO_0004616), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Colorectal Adenoma (EFO_0005406), Neurofibromatosis Type 1 (MONDO_0018975), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Papilloma (MONDO_0002363), Depressive Disorder (MONDO_0002050), Facial Pain (EFO_0009625), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Chronic Pain (HP_0012532), Tuberculosis (MONDO_0018076), Sarcoma (EFO_0000691), Major Depressive Disorder (MONDO_0002009), Oral Mucositis (EFO_1001904), Toothache (EFO_0010072), Macular Degeneration (EFO_0009606), Medulloblastoma (EFO_0002939), Uterine Cancer (MONDO_0002715), Rheumatic Disease (EFO_0005755), Covid-19 (MONDO_0100096), Colon Carcinoma (EFO_1001950), Injury (EFO_0000546), Rectal Carcinoma (MONDO_0044937), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Colorectal Neoplasm (EFO_0004142), Uterine Cervix Carcinoma In Situ (MONDO_0042487), Oral Squamous Cell Carcinoma (EFO_0000199), Osteoarthritis, Hip (EFO_1000786), Human Papilloma Virus Infection (EFO_0001668), Back Pain (HP_0003418), Renal Cell Carcinoma (EFO_0000681), Inflammation (MP_0001845), Bipolar Disorder (MONDO_0004985), Rheumatoid Arthritis (EFO_0000685), Recurrent Tonsillitis (HP_0011110), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Temporomandibular Joint Disorder (EFO_0005279), Head And Neck Malignant Neoplasia (EFO_0006859), Amyotrophic Lateral Sclerosis (MONDO_0004976), Nasopharyngeal Neoplasm (EFO_0004252), Melanoma (EFO_0000756), Squamous Cell Intraepithelial Neoplasia (MONDO_0024475), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1232 | Q17 | What gene does the drug Lipegfilgrastim target? | The drug Lipegfilgrastim targets the gene CSF3R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lipegfilgrastim%" OR LOWER(tradeNames_string) LIKE "%lipegfilgrastim%" OR LOWER(drugSynonyms_string) LIKE "%lipegfilgrastim%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4822', 'drugName': 'Lipegfilgrastim', 'tradeNames_string': 'Lonquex', 'drugSynonyms_string': 'Lipegfilgrastim, XM-22, XM22', 'linkedDiseasesDrug_string': 'Ewing Sarcoma (EFO_0000174), Lymphoma (EFO_0000574), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF3R (ENSG00000119535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.525 | Q17 | What gene does the drug Lonapegsomatropin target? | The drug Lonapegsomatropin targets the gene GHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lonapegsomatropin%" OR LOWER(tradeNames_string) LIKE "%lonapegsomatropin%" OR LOWER(drugSynonyms_string) LIKE "%lonapegsomatropin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2482', 'drugName': 'Lonapegsomatropin', 'tradeNames_string': 'Skytrofa, Stem-stat ortho', 'drugSynonyms_string': 'ACP-011, Lonapegsomatropin, Lonapegsomatropin tcgd, Lonapegsomatropin-tcgd, TRANSCONPEG-HGH, TransConPEG hGh, rhGH-PEG', 'linkedDiseasesDrug_string': 'Pituitary Dwarfism (EFO_1001109)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GHR (ENSG00000112964)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1654 | Q17 | What gene does the drug Terutroban target? | The drug Terutroban is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TBXA2R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%terutroban%" OR LOWER(tradeNames_string) LIKE "%terutroban%" OR LOWER(drugSynonyms_string) LIKE "%terutroban%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2143', 'drugName': 'Terutroban', 'tradeNames_string': 'Triplion', 'drugSynonyms_string': 'S18886, Terutroban', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TBXA2R (ENSG00000006638)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.908 | Q17 | What gene does the drug Dapoxetine target? | The drug Dapoxetine targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dapoxetine%" OR LOWER(tradeNames_string) LIKE "%dapoxetine%" OR LOWER(drugSynonyms_string) LIKE "%dapoxetine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3188', 'drugName': 'Dapoxetine', 'tradeNames_string': '', 'drugSynonyms_string': 'Dapoxetine, Kutub, LY-210448', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Sexual Dysfunction (EFO_0004714)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1904 | Q17 | What gene does the drug Azelastine target? | The drug Azelastine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azelastine%" OR LOWER(tradeNames_string) LIKE "%azelastine%" OR LOWER(drugSynonyms_string) LIKE "%azelastine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3567', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_string': "Astelin, Astepro, Astepro allergy, Azelastine hydrochloride, Children's astepro allergy, Optilast, Optivar, Rhinolast, Rhinolast allergy", 'drugSynonyms_string': 'A-5610, Azelastine hcl, Azelastine hydrochloride, E-0659, W-2979M', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Non-Allergic Rhinitis (EFO_0009364), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2721', 'drugName': 'Azelastine', 'tradeNames_string': '', 'drugSynonyms_string': 'Azelastine, NSC-758971', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Non-Allergic Rhinitis (EFO_0009364), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Eye Allergy (EFO_0005751), Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1242 | Q17 | What gene does the drug Dexmedetomidine Hydrochloride target? | The drug Dexmedetomidine Hydrochloride targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexmedetomidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dexmedetomidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dexmedetomidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6083', 'drugName': 'Dexmedetomidine Hydrochloride', 'tradeNames_string': 'Dexmedetomidine hydrochloride, Igalmi, Precedex', 'drugSynonyms_string': 'Cepedex, Dexdomitor, Dexdor, Dexmedetomidine hcl, Dexmedetomidine hydrochloride, Igalmi, Sedadex, Sileo', 'linkedDiseasesDrug_string': 'Agitation (HP_0000713), Pain (EFO_0003843), Delirium (EFO_0009267), Schizoaffective Disorder (EFO_0005411), Spinal Cord Cancer (MONDO_0003544), Brain Injury (MONDO_0043510), Amnesia (EFO_1001454), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.24 | Q17 | What gene does the drug Pegaptanib Sodium target? | The drug Pegaptanib Sodium targets the gene VEGFA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pegaptanib sodium%" OR LOWER(tradeNames_string) LIKE "%pegaptanib sodium%" OR LOWER(drugSynonyms_string) LIKE "%pegaptanib sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4833', 'drugName': 'Pegaptanib Sodium', 'tradeNames_string': 'Macugen', 'drugSynonyms_string': 'EYE-001, EYE001, EYEOO1, NX-1838, NX1838, Pegaptanib na, Pegaptanib sodium', 'linkedDiseasesDrug_string': 'Macular Degeneration (EFO_0009606), Retinal Vein Occlusion (EFO_1001157), Wet Macular Degeneration (EFO_0004683), Ocular Vascular Disease (EFO_0005753), Cystoid Macular Edema (MONDO_0007935), Von Hippel-Lindau Disease (MONDO_0008667), Age-Related Macular Degeneration (EFO_0001365), Macular Retinal Edema (MONDO_0003005)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VEGFA (ENSG00000112715)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.779 | Q17 | What gene does the drug Infigratinib target? | The drug Infigratinib targets 4 genes: FGFR2, FGFR1, FGFR3 and FGFR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%infigratinib%" OR LOWER(tradeNames_string) LIKE "%infigratinib%" OR LOWER(drugSynonyms_string) LIKE "%infigratinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1239', 'drugName': 'Infigratinib', 'tradeNames_string': '', 'drugSynonyms_string': 'BGJ-398, BGJ398, Bgj-398, Infigratinib, MVP-BGJ398, NVP-BGJ398', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Human Papilloma Virus Infection (EFO_0001668), Achondroplasia (MONDO_0007037), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Osteomalacia (EFO_1002027), Gastrointestinal Stromal Tumor (MONDO_0011719), Melanoma (EFO_0000756), Cervical Carcinoma (EFO_0001061), Glioblastoma Multiforme (EFO_0000519), Cholangiocarcinoma (EFO_0005221)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3003', 'drugName': 'Infigratinib Phosphate', 'tradeNames_string': 'Truseltiq', 'drugSynonyms_string': 'BGJ-398 phosphate, Infigratinib monophosphate, Infigratinib phosphate', 'linkedDiseasesDrug_string': 'Cholangiocarcinoma (EFO_0005221)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.65 | Q17 | What gene does the drug Elraglusib target? | The drug Elraglusib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GSK3B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%elraglusib%" OR LOWER(tradeNames_string) LIKE "%elraglusib%" OR LOWER(drugSynonyms_string) LIKE "%elraglusib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_576', 'drugName': 'Elraglusib', 'tradeNames_string': '', 'drugSynonyms_string': '9 ing 41, 9-ING-41, 9-ing-41, Elraglusib', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Malignant Bone Neoplasm (EFO_1000350), Myelofibrosis (MONDO_0044903), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Lung Neoplasm (MONDO_0021117), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GSK3B (ENSG00000082701)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1366 | Q17 | What gene does the drug Technetium Tc 99M Succimer target? | The drug Technetium Tc 99M Succimer targets the gene A2M. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%technetium tc 99m succimer%" OR LOWER(tradeNames_string) LIKE "%technetium tc 99m succimer%" OR LOWER(drugSynonyms_string) LIKE "%technetium tc 99m succimer%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2885', 'drugName': 'Technetium Tc 99M Succimer', 'tradeNames_string': 'Dmsa kidney reagent, Mpi dmsa kidney reagent, Nephroscan', 'drugSynonyms_string': '99mtc-dmsa, Nephroscan, Tc-99m dmsa, Technetium (99Mtc) Succimer, Technetium (99mtc) dimercaptosuccinic acid for injection, Technetium (99mtc) succimer, Technetium tc 99m succimer, Technetium tc-99m succimer, Technetium tc-99m succimer kit, Technetium-99 dimercaptosuccinate, Technetium-99-dmsa', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'A2M (ENSG00000175899)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.191 | Q17 | What gene does the drug Remifentanil target? | The drug Remifentanil targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remifentanil%" OR LOWER(tradeNames_string) LIKE "%remifentanil%" OR LOWER(drugSynonyms_string) LIKE "%remifentanil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1391', 'drugName': 'Remifentanil', 'tradeNames_string': '', 'drugSynonyms_string': 'GI 87084X, IDS-NR-005, Ramifentanyl, Remifentanil, Remifentanyl, Ultiva, Ultiva-', 'linkedDiseasesDrug_string': 'Ear Neoplasm (MONDO_0021233), Sleep Apnea (EFO_0003877), Opioid Use Disorder (EFO_0010702), Heart Disease (EFO_0003777), Premature Birth (EFO_0003917), Neoplasm (EFO_0000616), Postherpetic Neuralgia (MONDO_0041052), Stroke (EFO_0000712), Pain (EFO_0003843), Brain Neoplasm (EFO_0003833), Respiratory Depression (EFO_0009842), Obstructive Sleep Apnea (EFO_0003918), Morbid Obesity (EFO_0001074), Respiratory Insufficiency (HP_0002093), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_577', 'drugName': 'Remifentanil Hydrochloride', 'tradeNames_string': 'Ultiva', 'drugSynonyms_string': 'GI 87084B, GI-87084B, Remifentanil hcl, Remifentanil hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1630 | Q17 | What gene does the drug Itepekimab target? | The drug Itepekimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL33. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%itepekimab%" OR LOWER(tradeNames_string) LIKE "%itepekimab%" OR LOWER(drugSynonyms_string) LIKE "%itepekimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2908', 'drugName': 'Itepekimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Itepekimab, REGN-3500, REGN3500, Regn3500, SAR-440340, SAR440340, Sar440340', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Atopic Eczema (EFO_0000274), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL33 (ENSG00000137033)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1395 | Q17 | What gene does the drug Ublituximab target? | The drug Ublituximab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ublituximab%" OR LOWER(tradeNames_string) LIKE "%ublituximab%" OR LOWER(drugSynonyms_string) LIKE "%ublituximab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_780', 'drugName': 'Ublituximab', 'tradeNames_string': '', 'drugSynonyms_string': 'TG-1101, Ublituximab', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm Of Mature B-Cells (EFO_0000096), Multiple Sclerosis (MONDO_0005301), Neuromyelitis Optica (EFO_0004256), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Waldenstrom Macroglobulinemia (EFO_0009441), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1547 | Q17 | What gene does the drug Phloroglucinol target? | The drug Phloroglucinol targets 26 genes: CACNA1C, CACNA1H, CACNG2, CACNG7, CACNA2D1, CACNG6, CACNA1B, CACNG5, CACNG3, CACNG1, CACNB3, CACNB4, CACNA1S, CACNA2D3, CACNA1A, CACNA2D4, CACNA1D, CACNB2, CACNA1G, CACNA1I, CACNG8, CACNB1, CACNG4, CACNA1E, CACNA2D2 and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phloroglucinol%" OR LOWER(tradeNames_string) LIKE "%phloroglucinol%" OR LOWER(drugSynonyms_string) LIKE "%phloroglucinol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1320', 'drugName': 'Phloroglucinol', 'tradeNames_string': 'Spasfon, Spasfon-lyoc', 'drugSynonyms_string': 'Benezene-1,3,5-triol, Dilospan s, NSC-1572, Phloroglucin, Phloroglucinol, Sym-trihydroxybenzene', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 26}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.346 | Q17 | What gene does the drug S-777469 target? | The drug S-777469 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CNR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%s-777469%" OR LOWER(tradeNames_string) LIKE "%s-777469%" OR LOWER(drugSynonyms_string) LIKE "%s-777469%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_678', 'drugName': 'S-777469', 'tradeNames_string': '', 'drugSynonyms_string': 'S-777469', 'linkedDiseasesDrug_string': 'Atopic Eczema (EFO_0000274)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CNR2 (ENSG00000188822)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.400 | Q17 | What gene does the drug Oxaprozin target? | The drug Oxaprozin targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxaprozin%" OR LOWER(tradeNames_string) LIKE "%oxaprozin%" OR LOWER(drugSynonyms_string) LIKE "%oxaprozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2747', 'drugName': 'Oxaprozin', 'tradeNames_string': 'Daypro, Oxaprozin', 'drugSynonyms_string': 'NSC-310839, Oxaprozin, WY-21,743, WY-21743', 'linkedDiseasesDrug_string': 'Juvenile Idiopathic Arthritis (EFO_0002609), Rheumatic Disease (EFO_0005755), Osteoarthritis (MONDO_0005178), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3630', 'drugName': 'Oxaprozin Potassium', 'tradeNames_string': 'Daypro alta', 'drugSynonyms_string': 'Oxaprozin potassium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1393 | Q17 | What gene does the drug Insulin Purified Beef target? | The drug Insulin Purified Beef targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin purified beef%" OR LOWER(tradeNames_string) LIKE "%insulin purified beef%" OR LOWER(drugSynonyms_string) LIKE "%insulin purified beef%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2302', 'drugName': 'Insulin Purified Beef', 'tradeNames_string': 'Regular iletin ii', 'drugSynonyms_string': 'Insulin (beef), Insulin purified beef', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1876 | Q17 | What gene does the drug Cholecalciferol target? | The drug Cholecalciferol targets the gene VDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cholecalciferol%" OR LOWER(tradeNames_string) LIKE "%cholecalciferol%" OR LOWER(drugSynonyms_string) LIKE "%cholecalciferol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4543', 'drugName': 'Alfacalcidol', 'tradeNames_string': 'Alfa d, Etalpha, One-alpha', 'drugSynonyms_string': '.alpha.-calcidol, 1-alpha-vitamin d, 1-hydroxycholecalciferol, 1-hydroxyvitamin d3, 1.alpha-hydroxycholecalciferol, 1.alpha.(oh)d3, 1.alpha.-hydroxycholecalciferol, 1.alpha.-hydroxyvitamin d3, Alfacalcidol, Alfarol, Alpha d3, Alphacalcidol, Alpharol, Alsiodol, Bondiol, Einsalpha, Oxydevit, Tevabone, Un alfa, Un alpha', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Polycystic Ovary Syndrome (EFO_0000660), Postmenopausal Osteoporosis (EFO_0003854), Muscular Disease (EFO_0002970), Sudden Cardiac Arrest (EFO_0004278), Kidney Failure (EFO_1002048), Scoliosis (EFO_0004273), Calcification (EFO_0003837)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4232', 'drugName': 'Calcitriol', 'tradeNames_string': 'Calcijex, Calcitriol, Dihydroxycholecalciferol, Dihydroxyvitamin D 3, Rocaltrol, Silkis, Topitriol, Vectical', 'drugSynonyms_string': '1,25-dihydroxyvitamin d3, 1,25-hydroxylated vitamin d, 1alpha,25-dihydroxycholecalciferol, 1alpha,25-dihydroxyvitamin d3, Calcitriol, RO 21-5535, RO-21-5535, RO-215535', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Psoriasis (EFO_0000676), Postmenopausal Osteoporosis (EFO_0003854), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Klinefelter'S Syndrome (EFO_1001006), Myelodysplastic Syndrome (EFO_0000198), Mouth Neoplasm (EFO_0003868), Psoriasis Vulgaris (EFO_1001494), Prostate Adenocarcinoma (EFO_0000673), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Breast Cancer (MONDO_0007254), Hypertension (EFO_0000537), Renal Osteodystrophy (EFO_1001152), Attention Deficit Hyperactivity Disorder (EFO_0003888), Basal Cell Carcinoma (EFO_0004193), Cholangiocarcinoma (EFO_0005221), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Sepsis (HP_0100806), Hypoparathyroidism (EFO_0009451), Fibroma (EFO_0002424), Chronic Kidney Disease (EFO_0003884), Diabetic Nephropathy (EFO_0000401), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Hypophosphatemic Rickets (MONDO_0024300), Prediabetes Syndrome (EFO_1001121), Acute Kidney Injury (HP_0001919), Type 1 Diabetes Mellitus (MONDO_0005147), Hypocalcemia (HP_0002901), X-Linked Hypophosphatemia (Orphanet_89936), Osteopetrosis (MONDO_0017198)", 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2617', 'drugName': 'Cholecalciferol', 'tradeNames_string': "Accrete d3, Aciferol d3, Adcal-d3, Aviticol, Bio-vitamin d3, Biolife vitamin d3, Cacit d3, Calceos, Calci-d, Calcichew d3, Calcichew d3 fte, Calcichew d3 once daily, Caldrink d3, Calfovit d3, Colecal d3, Colecalciferol, Colekal-d3, Colevit d3, Cubicole d3, D-max, D-tracetten, D-vit3, D3 lemon melts, D3-50, Dekristol, Desunin, Dihydrocholesterol, Dlux 400, E-d3, Evacal d3, Fultium daily d3, Fultium-d3, Hux d3, Invita d3, Iso d3, Kora liquid, Natecal d3, Nature's remedy vitamin d3, Neo-d, Nphd3, Osteocaps d3, Plenachol, Pro d3, Pro d3 folic, Pro d3 forte, Royalvit d3, Stexerol-d3, Stivit-d3, Sunvit-d3 1,000, Sunvit-d3 10,000, Sunvit-d3 2,000, Sunvit-d3 20,000, Sunvit-d3 3,000, Sunvit-d3 400, Sunvit-d3 5,000, Sunvit-d3 50,000, Sunvit-d3 800, Synervit-d3, Theical d-3, Thorens, Vigantol, Vigantoletten, Vigantoletten 500, Vit d3 streuli, Vita-d3, Vitamin D 3, Zymad", 'drugSynonyms_string': '7-dehydrocholesterol, activated, AK R215 COMPONENT COLECALCIFEROL, AK-R215 COMPONENT COLECALCIFEROL, Cholecalciferol, Colecalciferol, Colecalciferolum, Delsterol, Delta-d, Deparal, Ebivit, NSC-375571, Provitina, Ricketon, Vitamin d, Vitamin d (cholecalciferol), Vitamin d assay system suitability, Vitamin d-3, Vitamin d3, Vitamin d3 (as cholecalciferol)', 'linkedDiseasesDrug_string': "Autism (EFO_0003758), Psoriasis (EFO_0000676), Postmenopausal Osteoporosis (EFO_0003854), Infection (EFO_0000544), Skin Cancer (MONDO_0002898), Male Infertility (EFO_0004248), Pregnancy (EFO_0002950), Malignant Colon Neoplasm (MONDO_0021063), Osteoporosis (EFO_0003882), Polycystic Ovary Syndrome (EFO_0000660), Vitamin D Deficiency (EFO_0003762), Atopic Eczema (EFO_0000274), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Bone Fracture (EFO_0003931), Hypogonadism (MONDO_0002146), Optic Neuritis (EFO_0007405), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Hiv-1 Infection (EFO_0000180), Breast Ductal Carcinoma In Situ (EFO_0000432), Colorectal Adenocarcinoma (EFO_0000365), Burn (EFO_0009516), Respiratory Failure (EFO_0009686), Prediabetes Syndrome (EFO_1001121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Barrett'S Esophagus (EFO_0000280), X-Linked Adrenoleukodystrophy (Orphanet_43), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Inborn Error Of Immunity (MONDO_0003778), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Urticaria (EFO_0005531), Hyperparathyroidism (EFO_0008506), Acute Myeloid Leukemia (EFO_0000222), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Sarcopenia (EFO_1000653), Abnormal Glucose Tolerance (EFO_0002546), Actinic Keratosis (EFO_0002496), Influenza (EFO_0007328), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Metabolic Syndrome (EFO_0000195), Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Irritable Bowel Syndrome (EFO_0000555), Aids (EFO_0000765), Ovarian Cancer (MONDO_0008170), Bronchiolitis (HP_0011950), Osteopenia (HP_0000938), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Cardiovascular Disease (EFO_0000319), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Epilepsy (EFO_0000474), Tibia Fracture (EFO_0003944), Common Cold (EFO_0007214), Colorectal Adenoma (EFO_0005406), Neurofibromatosis Type 1 (MONDO_0018975), Chronic Obstructive Pulmonary Disease (EFO_0000341), Gestational Diabetes (EFO_0004593), Urinary Tract Infection (EFO_0003103), Depressive Disorder (MONDO_0002050), Papilloma (MONDO_0002363), Staphylococcus Aureus Infection (EFO_0005681), Allergic Disease (MONDO_0005271), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Tuberculosis (MONDO_0018076), Type 1 Diabetes Mellitus (MONDO_0005147), Helicobacter Pylori Infectious Disease (EFO_1000961), Type 2 Diabetes Mellitus (MONDO_0005148), Iron Deficiency Anemia (HP_0001891), Hip Fracture (EFO_0003964), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Ulcerative Colitis (EFO_0000729), Hepatitis C Virus Infection (EFO_0003047), Inflammatory Bowel Disease (EFO_0003767), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Osteitis Deformans (EFO_0004261), Disorder Of Lipid Metabolism (Orphanet_309005), In Situ Carcinoma (MONDO_0004647), Nasal Congestion (HP_0001742), Malnutrition (EFO_0008572), Cognitive Impairment (HP_0100543), Gingivitis (MONDO_0002508), Melanoma (EFO_0000756), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.199 | Q17 | What gene does the drug Ixazomib Citrate target? | The drug Ixazomib Citrate targets 38 genes: PSMD6, PSMC5, PSMB11, PSMA4, PSMC6, PSMC2, PSMB2, PSMA6, PSMA2, PSMD13, PSMB9, ADRM1, PSMD2, PSMB8, PSMB4, PSMD11, SEM1, PSMB10, PSMD14, PSMA3, PSMB1, PSMD4, PSMB3, PSMA5, PSMD12, PSMB6, PSMD7, PSMB5, PSMD8, PSMD1, PSMC4, PSMA1, PSMA8, PSMC3, PSMC1, PSMA7, PSMD3 and PSMB7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ixazomib citrate%" OR LOWER(tradeNames_string) LIKE "%ixazomib citrate%" OR LOWER(drugSynonyms_string) LIKE "%ixazomib citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4407', 'drugName': 'Ixazomib Citrate', 'tradeNames_string': 'Ninlaro', 'drugSynonyms_string': 'Ixazomib citrate, MLN-9708, MLN9708', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Al Amyloidosis (MONDO_0019438), Neoplasm (EFO_0000616), Kaposi'S Sarcoma (EFO_0000558), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Plasmacytoma (EFO_0006738), Lymphoblastic Lymphoma (MONDO_0000873), Acute Myeloid Leukemia (EFO_0000222), Waldenstrom Macroglobulinemia (EFO_0009441), Glioblastoma Multiforme (EFO_0000519), Plasma Cell Leukemia (EFO_0006475)", 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'numberLinkedTargets': 38}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1173 | Q17 | What gene does the drug Sapanisertib target? | The drug Sapanisertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MTOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sapanisertib%" OR LOWER(tradeNames_string) LIKE "%sapanisertib%" OR LOWER(drugSynonyms_string) LIKE "%sapanisertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_271', 'drugName': 'Sapanisertib', 'tradeNames_string': '', 'drugSynonyms_string': 'CB-228, INK-128, INK128, Ink-128, MLN-0128, MLN0128, Mln-0128, Sapanisertib, TAK-228', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Pancreatic Neuroendocrine Tumor (EFO_1000045), Squamous Cell Lung Carcinoma (EFO_0000708), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Waldenstrom Macroglobulinemia (EFO_0009441), Endometrioid Carcinoma (EFO_0000466), Endometrial Neoplasm (EFO_0004230), Merkel Cell Skin Cancer (EFO_1001471), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Pancreatic Endocrine Carcinoma (EFO_0007416)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.320 | Q17 | What gene does the drug Dezamizumab target? | The drug Dezamizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene APCS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dezamizumab%" OR LOWER(tradeNames_string) LIKE "%dezamizumab%" OR LOWER(drugSynonyms_string) LIKE "%dezamizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5164', 'drugName': 'Dezamizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Anti - sap mab, Dezamizumab, GSK-2398852, GSK2398852, Gsk2398852, anti-SAP mAb', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Primary Systemic Amyloidosis (MONDO_0017816)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'APCS (ENSG00000132703)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1002 | Q17 | What gene does the drug Isoproterenol Hydrochloride target? | The drug Isoproterenol Hydrochloride targets 3 genes: ADRB3, ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isoproterenol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%isoproterenol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%isoproterenol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1200', 'drugName': 'Isoproterenol Hydrochloride', 'tradeNames_string': 'Aerolone, Imuprel, Isoprenaline, Isoproterenol hydrochloride, Isuprel, Norisodrine, Norisodrine aerotrol, Oriconazole, Vapo-iso', 'drugSynonyms_string': 'Aerotrol, Dl-isoprenaline hydrochloride, Euspiran, Isomenyl, Isoprenaline hydrochloride, Isoprenaline hydrochloride, dl-, Isopropylarterenol hydrochloride, Isoproterenol HCl, Isoproterenol hcl, Isoproterenol hydrochloride, Isovon, L-isoprenaline hydrochloride, Medihaler-Iso, Mistarel, NSC-37745, NSC-89747, Suscardia', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.223 | Q17 | What gene does the drug Ziprasidone Hydrochloride target? | The drug Ziprasidone Hydrochloride targets 3 genes: HTR2C, HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ziprasidone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%ziprasidone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%ziprasidone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3392', 'drugName': 'Ziprasidone Hydrochloride', 'tradeNames_string': 'Geodon, Zeldox, Ziprasidone hydrochloride', 'drugSynonyms_string': 'CP-88,059-1, CP-88059-1, CP-880591, Ziprasidone hydrochloride, Ziprasidone hydrochloride hydrate, Ziprasidone hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Cardiac Arrhythmia (EFO_0004269), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3393', 'drugName': 'Ziprasidone Hydrochloride', 'tradeNames_string': 'Geodon, Zeldox, Ziprasidone hydrochloride', 'drugSynonyms_string': 'CP-88,059-1, CP-88059-1, CP-880591, Ziprasidone hydrochloride, Ziprasidone hydrochloride hydrate, Ziprasidone hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Cardiac Arrhythmia (EFO_0004269), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3394', 'drugName': 'Ziprasidone Hydrochloride', 'tradeNames_string': 'Geodon, Zeldox, Ziprasidone hydrochloride', 'drugSynonyms_string': 'CP-88,059-1, CP-88059-1, CP-880591, Ziprasidone hydrochloride, Ziprasidone hydrochloride hydrate, Ziprasidone hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Cardiac Arrhythmia (EFO_0004269), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1220 | Q17 | What gene does the drug Diltiazem target? | The drug Diltiazem targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diltiazem%" OR LOWER(tradeNames_string) LIKE "%diltiazem%" OR LOWER(drugSynonyms_string) LIKE "%diltiazem%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_927', 'drugName': 'Diltiazem Hydrochloride', 'tradeNames_string': 'Adizem-60, Adizem-sr, Adizem-xl, Angiozem 60, Angiozem cr 120, Angiozem cr 90, Angitil sr 120, Angitil sr 180, Angitil sr 90, Angitil xl 240, Angitil xl 300, Anoheal, Bi-carzem sr, Bi-carzem xl, Britiazim, Calazem, Calcicard, Calcicard cr, Cardizem, Cardizem cd, Cardizem la, Cardizem sr, Cartia xt, Dilacor, Dilacor xr, Dilcardia sr, Dilcardia xl, Dilt-cd, Diltiazem hydrochloride, Diltiazem hydrochloride in dextrose 5%, Diltzac, Dilzem sr 120, Dilzem sr 60, Dilzem sr 90, Dilzem xl 120, Dilzem xl 180, Dilzem xl 240, Disogram sr, Horizem sr 120, Horizem sr 60, Horizem sr 90, Kentiazem, Kenzem sr, Optil, Optil sr 120, Optil sr 180, Optil sr 90, Optil xl 240, Optil xl 300, Retalzem 60, Slozem, Slozem 120, Slozem 180, Slozem 240, Taztia xt, Tiamex, Tiazac, Tildiem, Tildiem la 200, Tildiem la 300, Tildiem ret 120, Tildiem ret 90, Uard 120xl, Uard 180xl, Uard 240xl, Uard 300xl, Viazem xl, Zemret 180 xl, Zemret 240 xl, Zemret 300 xl, Zemtard 120 xl, Zemtard 180 xl, Zemtard 240 xl, Zemtard 300 xl, Zildil sr', 'drugSynonyms_string': 'Adizem, Altiazem, CRD-401, Cartia, Deltazen, Diladel, Dilpral, Dilrene, Diltiazem hcl, Diltiazem hydrochloride, Dilzem, Dilzene, Masdil, NSC-759576, RG 83606, RG-83606, Taztia, Zilden', 'linkedDiseasesDrug_string': 'Coronary Vasospasm (EFO_0004225), Hiv Infection (EFO_0000764), Angina Pectoris (EFO_0003913), Anal Fissure (HP_0012390), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Constipation (HP_0002019), Skin Disease (EFO_0000701), Colorectal Carcinoma (EFO_1001951), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3484', 'drugName': 'Diltiazem', 'tradeNames_string': '', 'drugSynonyms_string': 'Cardizem, Dilt-CD, Diltiazem, Diltiazem extended release, Diltzac, Ditiaz, Surazem, Tiamate, Tiazac', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Coronary Vasospasm (EFO_0004225), Coronary Artery Disease (EFO_0001645), Anal Fissure (HP_0012390), Covid-19 (MONDO_0100096), Hypotension (EFO_0005251), Colorectal Carcinoma (EFO_1001951), Atrial Fibrillation (EFO_0000275), Myocardial Ischemia (EFO_1001375), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Thrombotic Disease (MONDO_0000831), Drug Dependence (EFO_0003890), Hemorrhoid (EFO_0009552), Hypercholesterolemia (HP_0003124), Constipation (HP_0002019), Influenza (EFO_0007328), Anus Disease (EFO_0009660), Hiv Infection (EFO_0000764), Ischemia Reperfusion Injury (EFO_0002687), Heart Failure (EFO_0003144), Metabolic Syndrome (EFO_0000195), Skin Disease (EFO_0000701), Hypertrophic Cardiomyopathy (EFO_0000538), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3324', 'drugName': 'Diltiazem Malate', 'tradeNames_string': 'Tiamate', 'drugSynonyms_string': 'Diltiazem malate, MK-793', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.103 | Q17 | What gene does the drug Abiraterone Acetate target? | The drug Abiraterone Acetate targets the gene CYP17A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abiraterone acetate%" OR LOWER(tradeNames_string) LIKE "%abiraterone acetate%" OR LOWER(drugSynonyms_string) LIKE "%abiraterone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2354', 'drugName': 'Abiraterone Acetate', 'tradeNames_string': 'Yonsa, Zytiga', 'drugSynonyms_string': 'Abiraterone acetate, CB-7630, CB7630, NSC-748121, NSC-749227', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Congenital Adrenal Hyperplasia (MONDO_0018479), Metastatic Prostate Cancer (EFO_0000196), Renal Insufficiency (HP_0000083), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP17A1 (ENSG00000148795)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1655 | Q17 | What gene does the drug Chlormadinone Acetate target? | The drug Chlormadinone Acetate targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlormadinone acetate%" OR LOWER(tradeNames_string) LIKE "%chlormadinone acetate%" OR LOWER(drugSynonyms_string) LIKE "%chlormadinone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3940', 'drugName': 'Chlormadinone Acetate', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlormadinone, Chlormadinone acetate, Lutoral, NSC-92338, Normenon, RS-1280', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.949 | Q17 | What gene does the drug Trastuzumab Deruxtecan target? | The drug Trastuzumab Deruxtecan targets 2 genes: TOP1 and ERBB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trastuzumab deruxtecan%" OR LOWER(tradeNames_string) LIKE "%trastuzumab deruxtecan%" OR LOWER(drugSynonyms_string) LIKE "%trastuzumab deruxtecan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3205', 'drugName': 'Trastuzumab Deruxtecan', 'tradeNames_string': 'Enhertu', 'drugSynonyms_string': 'DS-8201, DS-8201a, Ds-8201a, Fam-trastuzumab deruxtecan-nxki, Trastuzumab deruxtecan, Trastuzumab deruxtecan nxki, Trastuzumab deruxtecan-nxki', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Osteosarcoma (EFO_0000637), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Colorectal Cancer (MONDO_0005575), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Non-Small Cell Lung Carcinoma (EFO_0003060), Digestive System Neoplasm (EFO_0008549), Metastasis (EFO_0009708), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3206', 'drugName': 'Trastuzumab Deruxtecan', 'tradeNames_string': 'Enhertu', 'drugSynonyms_string': 'DS-8201, DS-8201a, Ds-8201a, Fam-trastuzumab deruxtecan-nxki, Trastuzumab deruxtecan, Trastuzumab deruxtecan nxki, Trastuzumab deruxtecan-nxki', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Osteosarcoma (EFO_0000637), Breast Cancer (MONDO_0007254), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616), Colorectal Cancer (MONDO_0005575), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Non-Small Cell Lung Carcinoma (EFO_0003060), Digestive System Neoplasm (EFO_0008549), Metastasis (EFO_0009708), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1939 | Q17 | What gene does the drug Betamethasone Sodium Phosphate target? | The drug Betamethasone Sodium Phosphate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betamethasone sodium phosphate%" OR LOWER(tradeNames_string) LIKE "%betamethasone sodium phosphate%" OR LOWER(drugSynonyms_string) LIKE "%betamethasone sodium phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3118', 'drugName': 'Betamethasone Sodium Phosphate', 'tradeNames_string': 'Betam-ophtal, Betamethasone sodium phosphate, Betnesol, Betnesol-n, Celestone, Vistamethasone, Vistamethasone n', 'drugSynonyms_string': 'Betamethasone 21-phosphate disodium salt, Betamethasone disodium phosphate, Betamethasone sodium phosphate, NSC-90616', 'linkedDiseasesDrug_string': 'Nasal Congestion (HP_0001742), Tendinopathy (EFO_1001434), Osteoarthritis (MONDO_0005178), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Airway Obstruction (HP_0006536), Dry Eye Syndrome (EFO_1000906), Periarthritis (EFO_1001097), Low Back Pain (HP_0003419), Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1914 | Q17 | What gene does the drug Syl-1001 target? | The drug Syl-1001 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TRPV1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%syl-1001%" OR LOWER(tradeNames_string) LIKE "%syl-1001%" OR LOWER(drugSynonyms_string) LIKE "%syl-1001%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_981', 'drugName': 'Syl-1001', 'tradeNames_string': '', 'drugSynonyms_string': 'SYL-1001, SYL1001, Syl-1001, Tivanisiran', 'linkedDiseasesDrug_string': 'Dry Eye Syndrome (EFO_1000906), Ocular Pain (HP_0200026)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRPV1 (ENSG00000196689)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1127 | Q17 | What gene does the drug Bimatoprost target? | The drug Bimatoprost targets the gene PTGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bimatoprost%" OR LOWER(tradeNames_string) LIKE "%bimatoprost%" OR LOWER(drugSynonyms_string) LIKE "%bimatoprost%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_704', 'drugName': 'Bimatoprost', 'tradeNames_string': 'Bimatoprost, Durysta, Latisse, Lumigan', 'drugSynonyms_string': 'AGN 192024, AGN-192024, Bimatoprost, Prostamide', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Vitiligo (EFO_0004208), Graves Ophthalmopathy (EFO_1001466), Alopecia (MONDO_0004907), Hypotrichosis (MONDO_0003037), Open-Angle Glaucoma (EFO_0004190), Hypotrichosis Simplex (MONDO_0018914), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1052 | Q17 | What gene does the drug Perphenazine target? | The drug Perphenazine targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perphenazine%" OR LOWER(tradeNames_string) LIKE "%perphenazine%" OR LOWER(drugSynonyms_string) LIKE "%perphenazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_202', 'drugName': 'Perphenazine', 'tradeNames_string': 'Chlorpiprazine, Decentan, Fentazin, Perphenazine, Perphenazine Fendizoate, Trilafon, Trilafon-La', 'drugSynonyms_string': 'Etaperazine, NSC-150866, Perphenazine, Perphenazine fendizoate, Perphenazine maleate', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Nausea And Vomiting (HP_0002017), Agitation (HP_0000713), Dementia (HP_0000726), Anxiety (EFO_0005230), Cocaine Dependence (EFO_0002610), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1538 | Q17 | What gene does the drug Phentermine target? | The drug Phentermine targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phentermine%" OR LOWER(tradeNames_string) LIKE "%phentermine%" OR LOWER(drugSynonyms_string) LIKE "%phentermine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4285', 'drugName': 'Mephentermine Sulfate', 'tradeNames_string': 'Wyamine sulfate', 'drugSynonyms_string': 'Mephentermine sulfate, Mephentermine sulfate dihydrate, Mephentermine sulphate, Mephine, NSC-758424, Wyamine, Wyamine sulphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5704', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_string': 'Adipex-p, Fastin, Lomaira, Obestin-30, Oby-trim, Ona-mast, Phentermine hydrochloride, Suprenza, Tora, Wilpo', 'drugSynonyms_string': 'NSC-44090, Phentermine hcl, Phentermine hydrochloride, Phentermine hydrochloride civ, Zantryl', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2043', 'drugName': 'Phentermine', 'tradeNames_string': 'Duromine, Ionamin, Phentermine resin 30, Phentermine resin complex', 'drugSynonyms_string': 'NSC-759163, Phentermine, Phentermine resin, Phentermine resin complex, Qsiva', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Drug Dependence (EFO_0003890), Liver Disease (EFO_0001421), Obesity (EFO_0001073), Kidney Disease (EFO_0003086), Bulimia Nervosa (EFO_0005204), Morbid Obesity (EFO_0001074)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4353', 'drugName': 'Chlorphentermine Hydrochloride', 'tradeNames_string': 'Pre-sate', 'drugSynonyms_string': 'Chlorphentermine hcl, Chlorphentermine hydrochloride, NSC-76098, S-62, W 2426, W-2426', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4567', 'drugName': 'Mephentermine', 'tradeNames_string': '', 'drugSynonyms_string': 'Mephentermine', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_6215', 'drugName': 'Chlorphentermine', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorphentermine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.356 | Q17 | What gene does the drug Betamethasone Phosphoric Acid target? | The drug Betamethasone Phosphoric Acid targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betamethasone phosphoric acid%" OR LOWER(tradeNames_string) LIKE "%betamethasone phosphoric acid%" OR LOWER(drugSynonyms_string) LIKE "%betamethasone phosphoric acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2412', 'drugName': 'Betamethasone Phosphoric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Betamethasone phosphate, Betamethasone phosphoric acid', 'linkedDiseasesDrug_string': 'Nasal Congestion (HP_0001742), Pregnancy (EFO_0002950), Tendinopathy (EFO_1001434), Osteoarthritis (MONDO_0005178), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Airway Obstruction (HP_0006536), Dry Eye Syndrome (EFO_1000906), Periarthritis (EFO_1001097), Plantar Fasciitis (EFO_1001909), Low Back Pain (HP_0003419), Ulcerative Colitis (EFO_0000729)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.603 | Q17 | What gene does the drug Cetuximab target? | The drug Cetuximab targets the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cetuximab%" OR LOWER(tradeNames_string) LIKE "%cetuximab%" OR LOWER(drugSynonyms_string) LIKE "%cetuximab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1080', 'drugName': 'Cetuximab', 'tradeNames_string': 'Erbitux', 'drugSynonyms_string': 'ABP-494, C-225, C225, CMAB-009, CMAB009, Cetuximab, Cetuximab (genetical recombination), Cetuximab biosimilar (abp-494), IMC-225, IMC-C225, MOAB C225', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Head And Neck Carcinoma (MONDO_0002038), Complex Regional Pain Syndrome (EFO_1001998), Verrucous Carcinoma (EFO_0007535), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Adenoid Cystic Carcinoma (EFO_0000231), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Colon Carcinoma (EFO_1001950), Anal Neoplasm (EFO_0003835), Esophageal Carcinoma (EFO_0002916), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Endometrial Cancer (MONDO_0011962), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Ovarian Cancer (MONDO_0008170), Mouth Neoplasm (EFO_0003868), Colorectal Neoplasm (EFO_0004142), Gastric Adenocarcinoma (EFO_0000503), Cervical Carcinoma (EFO_0001061), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Neoplasm Of Oropharynx (MONDO_0021364), Tongue Neoplasm (EFO_0003871), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Hypopharyngeal Carcinoma (EFO_0002938), Oropharynx Cancer (EFO_1001931), Colorectal Cancer (MONDO_0005575), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Malignant Tumor Of Neck (MONDO_0021310), Peritoneum Cancer (MONDO_0002087), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Laryngeal Neoplasm (EFO_0003817), Oropharyngeal Carcinoma (MONDO_0044926), Biliary Tract Neoplasm (EFO_0003891), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Brain Cancer (MONDO_0001657), Rectum Cancer (EFO_1000657), Prolymphocytic Leukemia (MONDO_0001023), Head And Neck Malignant Neoplasia (EFO_0006859), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Urinary Bladder Cancer (MONDO_0001187), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Chordoma (MONDO_0008978), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Lung Cancer (MONDO_0008903), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Adenocarcinoma (EFO_0000228), Laryngeal Carcinoma (MONDO_0002358), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Neuralgia (EFO_0009430), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3231', 'drugName': 'Cetuximab Sarotalocan', 'tradeNames_string': '', 'drugSynonyms_string': 'ASP-1929, Cetuximab sarotalocan, Cetuximab sarotalocan sodium, Cetuximab-IRDye-700DX, Cetuximab-irdye 700dx conjugate, RM-1929', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1559 | Q17 | What gene does the drug Epitumomab Cituxetan target? | The drug Epitumomab Cituxetan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MUC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epitumomab cituxetan%" OR LOWER(tradeNames_string) LIKE "%epitumomab cituxetan%" OR LOWER(drugSynonyms_string) LIKE "%epitumomab cituxetan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_781', 'drugName': 'Epitumomab Cituxetan', 'tradeNames_string': '', 'drugSynonyms_string': 'Epitumomab cituxetan, Hmfg 1', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1350 | Q17 | What gene does the drug Memantine Hydrochloride target? | The drug Memantine Hydrochloride targets 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%memantine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%memantine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%memantine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4606', 'drugName': 'Memantine Hydrochloride', 'tradeNames_string': 'Akatinol, Ebixa, Marixino, Memantine, Memantine hydrochloride, Namenda, Namenda xr, Nemdatine, Valios', 'drugSynonyms_string': 'Acrescent, Auxura, Balaxur, FP-01, Memantine accord, Memantine hcl, Memantine hydrochloride, Memantine lek, Memantine merz, Memantine mylan, Memantine ratiopharm, Memary, NSC-102290, SUN-Y7017', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Gliosarcoma (EFO_1001465), Intracranial Subdural Hematoma (EFO_1001801), Alzheimer Disease (MONDO_0004975), Frontotemporal Dementia (MONDO_0017276), Amyotrophic Lateral Sclerosis (MONDO_0004976), Asperger Syndrome (EFO_0003757), Sickle Cell Anemia (MONDO_0011382), Dementia (HP_0000726), Central Nervous System Cancer (EFO_0000326), Learning Disability (MONDO_0004681), Brain Neoplasm (EFO_0003833), Influenza (EFO_0007328), Gambling Behaviour (EFO_0004699)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1359 | Q17 | What gene does the drug Betahistine target? | The drug Betahistine targets 2 genes: HRH3 and HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betahistine%" OR LOWER(tradeNames_string) LIKE "%betahistine%" OR LOWER(drugSynonyms_string) LIKE "%betahistine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6162', 'drugName': 'Betahistine', 'tradeNames_string': '', 'drugSynonyms_string': 'Betahistine', 'linkedDiseasesDrug_string': 'Body Weight Gain (EFO_0004566), Obesity (EFO_0001073), Hypercholesterolemia (HP_0003124), Attention Deficit Hyperactivity Disorder (EFO_0003888), Major Depressive Disorder (MONDO_0002009), Vertigo (HP_0002321)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6163', 'drugName': 'Betahistine', 'tradeNames_string': '', 'drugSynonyms_string': 'Betahistine', 'linkedDiseasesDrug_string': 'Body Weight Gain (EFO_0004566), Obesity (EFO_0001073), Hypercholesterolemia (HP_0003124), Attention Deficit Hyperactivity Disorder (EFO_0003888), Major Depressive Disorder (MONDO_0002009), Vertigo (HP_0002321)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.947 | Q17 | What gene does the drug Jnj-37822681 target? | The drug Jnj-37822681 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%jnj-37822681%" OR LOWER(tradeNames_string) LIKE "%jnj-37822681%" OR LOWER(drugSynonyms_string) LIKE "%jnj-37822681%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2599', 'drugName': 'Jnj-37822681', 'tradeNames_string': '', 'drugSynonyms_string': 'JNJ-37822681, Jnj-37822681', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.348 | Q17 | What gene does the drug Siplizumab target? | The drug Siplizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%siplizumab%" OR LOWER(tradeNames_string) LIKE "%siplizumab%" OR LOWER(drugSynonyms_string) LIKE "%siplizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1616', 'drugName': 'Siplizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'MEDI-507, Siplizumab', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Chronic Kidney Disease (EFO_0003884), Leukemia (EFO_0000565), Graft Versus Host Disease (MONDO_0013730), Lymphoma (EFO_0000574), Kidney Disease (EFO_0003086), Kidney Failure (EFO_1002048), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD2 (ENSG00000116824)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.606 | Q17 | What gene does the drug Enalapril target? | The drug Enalapril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enalapril%" OR LOWER(tradeNames_string) LIKE "%enalapril%" OR LOWER(drugSynonyms_string) LIKE "%enalapril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6274', 'drugName': 'Enalapril Maleate', 'tradeNames_string': 'Ednyt, Enalapril maleate, Enapren, Epaned, Epaned kit, Innovace, Pralenal 10, Pralenal 2.5, Pralenal 20, Pralenal 5, Renitec, Vasotec, Xanef', 'drugSynonyms_string': 'Enalapril maleate, MK-421, NSC-758143', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Intracerebral Hemorrhage (EFO_0005669), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Proteinuria (HP_0000093), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2276', 'drugName': 'Enalaprilat', 'tradeNames_string': 'Vasotec', 'drugSynonyms_string': 'Enalaprilat, MK-421, MK-422', 'linkedDiseasesDrug_string': 'Dilated Cardiomyopathy (EFO_0000407), Hypertension (EFO_0000537), Keloid (EFO_0004212)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1101', 'drugName': 'Enalaprilat', 'tradeNames_string': 'Enalaprilat, Vasotec', 'drugSynonyms_string': 'Enalapril diacid dihydrate, Enalapril diacid dihydrate anhydrous, Enalaprilat, Enalaprilat dihydrate, MK-422, NSC-760053, Vasotec i.v.', 'linkedDiseasesDrug_string': 'Dilated Cardiomyopathy (EFO_0000407), Hypertension (EFO_0000537), Keloid (EFO_0004212)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3756', 'drugName': 'Enalapril', 'tradeNames_string': '', 'drugSynonyms_string': 'C09AA02, Enalapril, Lexxel, Olinapril, Vaseretic, Vasotec', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Erectile Dysfunction (EFO_0004234), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Essential Hypertension (MONDO_0001134), Iga Glomerulonephritis (EFO_0004194), St Elevation Myocardial Infarction (EFO_0008585), Cardiotoxicity (EFO_1001482), Myocardial Ischemia (EFO_1001375), Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Intracerebral Hemorrhage (EFO_0005669), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Acute Myeloid Leukemia (EFO_0000222), Pseudohypoaldosteronism (MONDO_0018638), Stroke (EFO_0000712), Proteinuria (HP_0000093), Influenza (EFO_0007328), Rheumatoid Arthritis (EFO_0000685), Cardiomyopathy (EFO_0000318), Chagas Cardiomyopathy (EFO_0005529), Lymphoid Leukemia (EFO_0004289), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Heart Failure (EFO_0003144), Melanoma (EFO_0000756), Type 1 Diabetes Mellitus (MONDO_0005147), Barrett'S Esophagus (EFO_0000280), Ischemia (EFO_0000556)", 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.719 | Q17 | What gene does the drug Sodium Nitroprusside target? | The drug Sodium Nitroprusside targets 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sodium nitroprusside%" OR LOWER(tradeNames_string) LIKE "%sodium nitroprusside%" OR LOWER(drugSynonyms_string) LIKE "%sodium nitroprusside%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3464', 'drugName': 'Sodium Nitroprusside', 'tradeNames_string': 'Nipride, Nitropress, Sodium nitroprusside', 'drugSynonyms_string': 'NSC-755844, Nipruss, Nitroprusside sodium, Sodium nitroferricyanide, Sodium nitroprusside, Sodium nitroprusside anhydrous, Sodium nitroprusside dihydrate, Sodium nitroprusside hydrate', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Sarcopenia (EFO_1000653), Anemia (Phenotype) (EFO_0004272), Hemorrhage (MP_0001914), Hypertension (EFO_0000537), Obesity (EFO_0001073), Cardiovascular Disease (EFO_0000319), St Elevation Myocardial Infarction (EFO_0008585), Inflammation (MP_0001845), Aging (GO_0007568), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.118 | Q17 | What gene does the drug Flavoxate Hydrochloride target? | The drug Flavoxate Hydrochloride targets 8 genes: PDE7B, PDE7A, PDE8A, PDE4D, PDE4B, PDE4A, PDE4C and PDE8B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flavoxate hydrochloride%" OR LOWER(tradeNames_string) LIKE "%flavoxate hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%flavoxate hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1987', 'drugName': 'Flavoxate Hydrochloride', 'tradeNames_string': 'Flavoxate hydrochloride, Urispas, Urispas 200', 'drugSynonyms_string': 'DW-61, Flavoxate, Flavoxate hcl, Flavoxate hydrochloride, NSC-114649', 'linkedDiseasesDrug_string': 'Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Dysuria (EFO_0003901), Prostatitis (EFO_0003830)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_1988', 'drugName': 'Flavoxate Hydrochloride', 'tradeNames_string': 'Flavoxate hydrochloride, Urispas, Urispas 200', 'drugSynonyms_string': 'DW-61, Flavoxate, Flavoxate hcl, Flavoxate hydrochloride, NSC-114649', 'linkedDiseasesDrug_string': 'Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Dysuria (EFO_0003901), Prostatitis (EFO_0003830)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_1989', 'drugName': 'Flavoxate Hydrochloride', 'tradeNames_string': 'Flavoxate hydrochloride, Urispas, Urispas 200', 'drugSynonyms_string': 'DW-61, Flavoxate, Flavoxate hcl, Flavoxate hydrochloride, NSC-114649', 'linkedDiseasesDrug_string': 'Urinary Tract Infection (EFO_0003103), Urethritis (EFO_0003878), Dysuria (EFO_0003901), Prostatitis (EFO_0003830)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE8B (ENSG00000113231), PDE8A (ENSG00000073417), PDE7A (ENSG00000205268), PDE7B (ENSG00000171408), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.617 | Q17 | What gene does the drug Lisdexamfetamine Dimesylate target? | The drug Lisdexamfetamine Dimesylate targets 3 genes: SLC6A2, SLC6A3 and SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(tradeNames_string) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(drugSynonyms_string) LIKE "%lisdexamfetamine dimesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2130', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2131', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2132', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1013 | Q17 | What gene does the drug Bromocriptine Mesylate target? | The drug Bromocriptine Mesylate targets 3 genes: DRD3, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_string) LIKE "%bromocriptine mesylate%" OR LOWER(drugSynonyms_string) LIKE "%bromocriptine mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4746', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_string': 'Bromocriptine mesylate, Cycloset, Parlodel', 'drugSynonyms_string': '2-bromoergocryptine mesylate, Bromocriptine mesilate, Bromocriptine mesylate, Bromocriptine methanesulfonate, CB-154, CB-154 MESYLATE, Cb-154 mesilate, NSC-755915', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Acromegaly (EFO_1001485), Infertility (EFO_0000545), Parkinson Disease (MONDO_0005180), Adenoma (EFO_0000232), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperprolactinemia (EFO_0007319)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1265 | Q17 | What gene does the drug Ave-9633 target? | The drug Ave-9633 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD33. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ave-9633%" OR LOWER(tradeNames_string) LIKE "%ave-9633%" OR LOWER(drugSynonyms_string) LIKE "%ave-9633%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3062', 'drugName': 'Ave-9633', 'tradeNames_string': '', 'drugSynonyms_string': 'AVE-9633, Ave-9633, HUMY9-6', 'linkedDiseasesDrug_string': 'Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD33 (ENSG00000105383)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1489 | Q17 | What gene does the drug Sumatriptan Succinate target? | The drug Sumatriptan Succinate targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sumatriptan succinate%" OR LOWER(tradeNames_string) LIKE "%sumatriptan succinate%" OR LOWER(drugSynonyms_string) LIKE "%sumatriptan succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1609', 'drugName': 'Sumatriptan Succinate', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugSynonyms_string': 'GR 43175C, GR-43175C, NSC-760362, Sumatriptan (as succinate), Sumatriptan galpharm, Sumatriptan succinate, Treximet', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1610', 'drugName': 'Sumatriptan Succinate', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugSynonyms_string': 'GR 43175C, GR-43175C, NSC-760362, Sumatriptan (as succinate), Sumatriptan galpharm, Sumatriptan succinate, Treximet', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Migraine With Aura (MONDO_0005475)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.489 | Q17 | What gene does the drug Acalabrutinib Maleate target? | The drug Acalabrutinib Maleate targets the gene BTK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acalabrutinib maleate%" OR LOWER(tradeNames_string) LIKE "%acalabrutinib maleate%" OR LOWER(drugSynonyms_string) LIKE "%acalabrutinib maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6297', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_string': 'Calquence', 'drugSynonyms_string': 'Acalabrutinib maleate, Acalabrutinib maleate anhydrous, Calquence maleate', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Mantle Cell Lymphoma (EFO_1001469)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1711 | Q17 | What gene does the drug Phenmetrazine target? | The drug Phenmetrazine targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenmetrazine%" OR LOWER(tradeNames_string) LIKE "%phenmetrazine%" OR LOWER(drugSynonyms_string) LIKE "%phenmetrazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4239', 'drugName': 'Phenmetrazine Hydrochloride', 'tradeNames_string': 'Preludin', 'drugSynonyms_string': 'NSC-405728, Phenmetraline hydrochloride, Phenmetrazine chloride, Phenmetrazine hcl, Phenmetrazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4238', 'drugName': 'Phenmetrazine Hydrochloride', 'tradeNames_string': 'Preludin', 'drugSynonyms_string': 'NSC-405728, Phenmetraline hydrochloride, Phenmetrazine chloride, Phenmetrazine hcl, Phenmetrazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5962', 'drugName': 'Phenmetrazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Phenmetrazine, Preludin, Trans-phenmetrazine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5961', 'drugName': 'Phenmetrazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Phenmetrazine, Preludin, Trans-phenmetrazine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.787 | Q17 | What gene does the drug Fluticasone Propionate target? | The drug Fluticasone Propionate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_string) LIKE "%fluticasone propionate%" OR LOWER(drugSynonyms_string) LIKE "%fluticasone propionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5997', 'drugName': 'Fluticasone Propionate', 'tradeNames_string': 'Aerivio spiromax, Airflusal forspiro, Armonair digihaler, Armonair respiclick, Cutivate, Flixonase, Flixotide, Flonase, Flonase allergy relief, Flovent, Flovent diskus 100, Flovent diskus 250, Flovent diskus 50, Flovent hfa, Fluticasone propionate, Flutiform, Nasofan, Pirinase, Sereflo, Seretide 100, Seretide 125, Seretide 250, Seretide 50, Seretide 500, Sirdupla, Xhance', 'drugSynonyms_string': 'CCI 18781, CCI-18781, CCI18781, FLOVENT, Fluticaps, Fluticasone, Fluticasone propionate, Fluticasone propionate , Fluticasone-17-propionate, NSC-759889, Opn-375, Optinose, PF-00241939, R01AD08', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Covid-19 (MONDO_0100096), Bronchogenic Carcinoma (EFO_1001942), Allergic Rhinitis (EFO_0005854), Bronchiolitis Obliterans (EFO_0007183), Nasal Polyposis (HP_0100582), Bronchiolitis (HP_0011950), Stridor (HP_0010307), Blepharitis (EFO_0009536), Seasonal Allergic Rhinitis (EFO_0003956), Atopic Eczema (EFO_0000274), Emphysema (EFO_0000464), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Chronic Rhinosinusitis (EFO_1000024), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Polyp (EFO_0000662), Nasal Congestion (HP_0001742), Obstructive Sleep Apnea (EFO_0003918), Chronic Bronchitis (EFO_0006505), Croup (EFO_0007227), Eosinophilic Esophagitis (EFO_0004232), Skin Disease (EFO_0000701), Rhinitis (EFO_0008521)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.881 | Q17 | What gene does the drug Fosdagrocorat target? | The drug Fosdagrocorat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosdagrocorat%" OR LOWER(tradeNames_string) LIKE "%fosdagrocorat%" OR LOWER(drugSynonyms_string) LIKE "%fosdagrocorat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2507', 'drugName': 'Fosdagrocorat', 'tradeNames_string': '', 'drugSynonyms_string': 'Fosdagrocorat, PF-04171327', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1555 | Q17 | What gene does the drug Tolazamide target? | The drug Tolazamide targets 2 genes: KCNJ11 and ABCC8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tolazamide%" OR LOWER(tradeNames_string) LIKE "%tolazamide%" OR LOWER(drugSynonyms_string) LIKE "%tolazamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2335', 'drugName': 'Tolazamide', 'tradeNames_string': 'Tolazamide, Tolinase', 'drugSynonyms_string': 'NSC-70762, Tolazamide, U-17835', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.567 | Q17 | What gene does the drug Asg-5Me target? | The drug Asg-5Me is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 16 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, SLC44A4, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asg-5me%" OR LOWER(tradeNames_string) LIKE "%asg-5me%" OR LOWER(drugSynonyms_string) LIKE "%asg-5me%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'tradeNames_string': '', 'drugSynonyms_string': 'ASG-5ME, Asg-5me', 'linkedDiseasesDrug_string': 'Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'tradeNames_string': '', 'drugSynonyms_string': 'ASG-5ME, Asg-5me', 'linkedDiseasesDrug_string': 'Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.254 | Q17 | What gene does the drug Sonidegib target? | The drug Sonidegib targets the gene SMO. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sonidegib%" OR LOWER(tradeNames_string) LIKE "%sonidegib%" OR LOWER(drugSynonyms_string) LIKE "%sonidegib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3128', 'drugName': 'Sonidegib', 'tradeNames_string': '', 'drugSynonyms_string': 'Erismodegib, LDE 225, LDE-225, LDE225, NVP-LDE 225, NVP-LDE-225, NVP-LDE225, Sonidegib', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Breast Neoplasm (EFO_0003869), Multiple Myeloma (EFO_0001378), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medulloblastoma (EFO_0002939), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Graft Versus Host Disease (MONDO_0013730), Skin Basal Cell Carcinoma (MONDO_0005341), Basal Cell Carcinoma (EFO_0004193), Ovarian Cancer (MONDO_0008170), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3933', 'drugName': 'Sonidegib Phosphate', 'tradeNames_string': 'Odomzo', 'drugSynonyms_string': 'Erismodegib phosphate, Sonidegib diphosphate, Sonidegib phosphate', 'linkedDiseasesDrug_string': 'Basal Cell Carcinoma (EFO_0004193)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.242 | Q17 | What gene does the drug Nerispirdine target? | The drug Nerispirdine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 50 genes: KCNB1, KCND2, KCNA7, KCNG3, SCN7A, SCN9A, SCN10A, KCNA4, SCN4A, KCNQ1, KCNQ3, KCNA1, KCNC4, KCNS1, KCNG2, KCNA6, SCN8A, SCN2A, KCNV2, KCNA5, KCNH2, KCNS3, SCN3A, KCNQ4, KCND3, KCNG1, KCNB2, KCNH6, KCNC3, KCNG4, KCNF1, SCN5A, KCNH8, KCNS2, KCNA3, KCNQ2, SCN1A, KCNH4, KCNA10, KCNC2, KCNC1, KCNH1, SCN11A, KCNH3, KCNV1, KCNQ5, KCND1, KCNA2, KCNH7 and KCNH5 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nerispirdine%" OR LOWER(tradeNames_string) LIKE "%nerispirdine%" OR LOWER(drugSynonyms_string) LIKE "%nerispirdine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3950', 'drugName': 'Nerispirdine', 'tradeNames_string': '', 'drugSynonyms_string': 'HP-184, HP184, Nerispirdine, Nerispirdine hydrochloride', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 50}, {'UUID': 'DrugGeneTargets_v2_3951', 'drugName': 'Nerispirdine', 'tradeNames_string': '', 'drugSynonyms_string': 'HP-184, HP184, Nerispirdine, Nerispirdine hydrochloride', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 50}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.176 | Q17 | What gene does the drug Tofacitinib target? | The drug Tofacitinib targets 4 genes: JAK3, TYK2, JAK1 and JAK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tofacitinib%" OR LOWER(tradeNames_string) LIKE "%tofacitinib%" OR LOWER(drugSynonyms_string) LIKE "%tofacitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4953', 'drugName': 'Tofacitinib', 'tradeNames_string': '', 'drugSynonyms_string': '550, CP 690550, CP- 690 550, CP-690, CP-690,550, CP-690,550 FREE BASE, CP-690-550, CP-690550, CP-690550 FREE BASE, CP690,550, CP690550, Cp-690 free base, Tasocitinib, Tofacitinib', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Pneumonia (EFO_0003106), Ankylosing Spondylitis (EFO_0003898), Sjogren Syndrome (EFO_0000699), Covid-19 (MONDO_0100096), Dry Eye Syndrome (EFO_1000906), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Myasthenia Gravis (EFO_0004991), Cutaneous Lupus Erythematosus (EFO_0003834), Ulcerative Colitis (EFO_0000729), Psoriasis Vulgaris (EFO_1001494), Crohn'S Disease (EFO_0000384), Juvenile Idiopathic Arthritis (EFO_0002609), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Pouchitis (EFO_0003921), Chronic Granulomatous Disease (MONDO_0018305), Polymyalgia Rheumatica (EFO_0008518), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540), Alopecia Areata (EFO_0004192), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Myositis (EFO_0000783), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Sarcoidosis (MONDO_0019338), Chronic Kidney Disease (EFO_0003884), Discoid Lupus Erythematosus (MONDO_0019558), Colitis (EFO_0003872), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)", 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3515', 'drugName': 'Tofacitinib Citrate', 'tradeNames_string': 'Xeljanz, Xeljanz xr', 'drugSynonyms_string': 'CP-690,550-10, CP-690550-10, Cp-690550 citrate, Tasocitinib citrate, Tasocitinib monocitrate, Tofacitinib citrate, Tofacitinib monocitrate', 'linkedDiseasesDrug_string': 'Discoid Lupus Erythematosus (MONDO_0019558), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.824 | Q17 | What gene does the drug Meprednisone target? | The drug Meprednisone targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%meprednisone%" OR LOWER(tradeNames_string) LIKE "%meprednisone%" OR LOWER(drugSynonyms_string) LIKE "%meprednisone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5378', 'drugName': 'Meprednisone', 'tradeNames_string': 'Betapar', 'drugSynonyms_string': 'Meprednisone, NSC-527579, SCH 4358, SCH-4358', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.983 | Q17 | What gene does the drug Bnc-210 target? | The drug Bnc-210 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CHRNA7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bnc-210%" OR LOWER(tradeNames_string) LIKE "%bnc-210%" OR LOWER(drugSynonyms_string) LIKE "%bnc-210%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1009', 'drugName': 'Bnc-210', 'tradeNames_string': '', 'drugSynonyms_string': 'BNC-210, BNC210, Bnc-210, Bnc210, Iw-2143', 'linkedDiseasesDrug_string': 'Social Anxiety Disorder (EFO_1001917), Post-Traumatic Stress Disorder (EFO_0001358), Agitation (HP_0000713)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1476 | Q17 | What gene does the drug Sildenafil Citrate target? | The drug Sildenafil Citrate targets the gene PDE5A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sildenafil citrate%" OR LOWER(tradeNames_string) LIKE "%sildenafil citrate%" OR LOWER(drugSynonyms_string) LIKE "%sildenafil citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4134', 'drugName': 'Sildenafil Citrate', 'tradeNames_string': 'Revatio, Sildenafil citrate, Viagra', 'drugSynonyms_string': 'NSC-744009, NSC-758669, Sildenafil (as citrate), Sildenafil citrate, UK-92,480-10, UK-92480-10', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Pulmonary Hypertension (MONDO_0005149), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), Dysmenorrhea (HP_0100607), Diffuse Scleroderma (EFO_0000404), Hepatitis C Virus Infection (EFO_0003047), Prostate Cancer (MONDO_0008315), Preeclampsia (EFO_0000668), Fetal Growth Restriction (EFO_0000495), Hand-Foot Syndrome (EFO_1001893), Hypertension (EFO_0000537), Persistent Fetal Circulation Syndrome (EFO_1001103), Wilms Tumor (MONDO_0006058), Emphysema (EFO_0000464), Pulmonary Edema (EFO_1001134), Limited Scleroderma (EFO_1001017), Concussion (EFO_0011023), Post-Concussion Syndrome (EFO_1001827), Connective Tissue Disease (EFO_1001986), Stroke (EFO_0000712), Infertility (EFO_0000545), Chronic Obstructive Pulmonary Disease (EFO_0000341), Brain Neoplasm (EFO_0003833), Waldenstrom Macroglobulinemia (EFO_0009441), Brain Injury (MONDO_0043510), Age-Related Macular Degeneration (EFO_0001365), Asphyxia Neonatorum (EFO_1000824), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Raynaud Disease (EFO_1001145), Idiopathic And/Or Familial Pulmonary Arterial Hypertension (MONDO_0008347), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1262 | Q17 | What gene does the drug Rosuvastatin Calcium target? | The drug Rosuvastatin Calcium targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rosuvastatin calcium%" OR LOWER(tradeNames_string) LIKE "%rosuvastatin calcium%" OR LOWER(drugSynonyms_string) LIKE "%rosuvastatin calcium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5208', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_string': 'Crestor, Ezallor, Ezallor sprinkle, Rosuvastatin calcium', 'drugSynonyms_string': 'Fortius, NSC-747274, NSC-758930, Rostar, Rosuvastatin (as calcium), Rosuvastatin calcium, Rosuvastatin calcium salt, Rosuvastatin hemicalcium, Rozavel, S-4522, Suvikan, ZD-4522, ZD-4522 (CALCIUM SALT), ZD-4522 CALCIUM, ZD4522 (CALCIUM SALT), ZD4522 CALCIUM', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipoproteinemia Type 3 (MONDO_0018473), Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Ischemic Stroke (HP_0002140), Hyperlipidemia (MONDO_0021187), Chronic Hepatitis B Virus Infection (EFO_0004239), Combined Hyperlipidemia (Orphanet_79211), Heart Failure (EFO_0003144), Familial Hypercholesterolemia (EFO_0004911), Hypertension (EFO_0000537), Hypercholesterolemia (HP_0003124), Acute Coronary Syndrome (EFO_0005672), Disorder Of Lipid Metabolism (Orphanet_309005), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1280 | Q17 | What gene does the drug Gtx-758 target? | The drug Gtx-758 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gtx-758%" OR LOWER(tradeNames_string) LIKE "%gtx-758%" OR LOWER(drugSynonyms_string) LIKE "%gtx-758%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5190', 'drugName': 'Gtx-758', 'tradeNames_string': 'Capesaris', 'drugSynonyms_string': 'Gtx 758, Gtx-758', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.751 | Q17 | What gene does the drug Ximelagatran target? | The drug Ximelagatran targets the gene F2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ximelagatran%" OR LOWER(tradeNames_string) LIKE "%ximelagatran%" OR LOWER(drugSynonyms_string) LIKE "%ximelagatran%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2369', 'drugName': 'Ximelagatran', 'tradeNames_string': 'Exanta (proposed)', 'drugSynonyms_string': 'Exanta, H 376/95, Ximelagatran', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Thromboembolism (HP_0001907), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.